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METHODS FOR TREATING CONGESTIVE 	 mately 15 distinct structurally-related isoforms (Lemke, Mol.
HEART FAILURE
	
	 Cell. Neurosci. 7: 247-262, 1996 and Peles and Yarden,
BioEssays 15: 815-824, 1993). The first-identified isoforms
CROSS-REFERENCE TO RELATED	 ofNRG-1 included Neu Differentiation Factor (NDF; Peles et
APPLICATIONS
	
	
5 al., Cell 69, 205-216, 1992 and Wen et al., Cell 69, 559-572,
1992), Heregulin (HRG; Holmes et al., Science 256: 1205-
This applicationis a divisional of, and claims priority from, 	 1210, 1992), Acetylcholine Receptor Inducing Activity
U.S. patent application Ser. No. 09/298,121, filed Apr. 23, 	 (ARIA; Falls et al., Cell 72: 801-815, 1993), and the glial
1999, now U.S. Pat. No. 6,635,249, issued Oct. 21, 2003.
	
	 growth factors GGF1, GGF2, and GGF3 (Marchionni et al.
io Nature 362: 312-8, 1993).
STATEMENT AS TO FEDERALLY SPONSORED 	 The Nrg-2 gene was identified by homology cloning
RESEARCH	 (Chang et al., Nature 387:509-512, 1997; Carraway et al.,
Nature 387:512-516, 1997; and Higashiyama et al., J. Bio-
This work was supported in part by NIH Grants HL-38189, 	 chem. 122: 675-680, 1997) and through genomic approaches
HL-36141, and a NASA award. The government has certain 15 (Busfield et al., Mol. Cell. Biol. 17:4007-4014,1997). NRG-2
rights in the invention.	 cDNAs are also known as Neural- and Thymus-DerivedActi-
vator of ErbB Kinases (NTAK; Genbank Accession No.
FIELD OF THE INVENTION	 A13005060), Divergent of Neuregulin (Don-1), and Cerebel-
lum-Derived Growth Factor (CDGF; PCT application WO
The field of the invention is treatment and prevention of 20 97/09425). Experimental evidence shows that cells express-
congestive heart failure. 	 ing ErbB4 or the ErbB2/ErbB4 combination are likely to
show a particularly robust response to NRG-2 (Pinkas-Kra-
BACKGROUND OF THE INVENTION	 marski et al., Mol. Cell. Biol. 18: 6090-6101, 1998). The
Nrg-3 gene product (Zhang et al., supra) is also known to bind
Congestive heart failure, one of the leading causes of death 25 and activate ErbB4 receptors (Hijazi et al., Int. J. Oncol.
in industrialized nations, results from an increased workload 	 13:1061-1067, 1998).
on the heart and a progressive decrease in its pumping ability.	 An EGF-like domain is present at the core of all forms of
Initially, the increased workload that results from high blood	 NRGs, and is required for binding and activating ErbB recep-
pressure or loss of contractile tissue induces compensatory 	 tors. Deduced amino acid sequences of the EGF-like domains
cardiomyocyte hypertrophy and thickening of the left ven- 30 encoded in the three genes are approximately 30-40% iden-
tricular wall, thereby enhancing contractility and maintaining 	 tical (pairwise comparisons). Further, there appear to be at
cardiac function. However, over time, the left ventricular 	 least two sub-forms of EGF-like domains in NRG-1 and
chamber dilates, systolic pump function deteriorates, cardi-	 NRG-2, which may confer different bioactivities and tissue-
omyocytes undergo apoptotic cell death, and myocardial	 specific potencies.
function progressively deteriorates. 	 35	 Cellular responses to NRGs are mediated through the NRG
Factors that underlie congestive heart failure include high 	 receptor tyrosine kinases EGFR, ErbB2, ErbB3, and ErbB4
blood pressure, ischemic heart disease, exposure to car-	 of the epidermal growth factor receptor family. High-affinity
diotoxic compounds such as the anthracycline antibiotics, 	 binding of all NRGs is mediated principally via either ErbB3
and genetic defects known to increase the risk of heart failure. 	 or ErbB4. Binding of NRG ligands leads to dimerization with
Neuregulins (NRGs) and NRG receptors comprise a 40 other ErbB subunits and transactivation by phosphorylation
growth factor-receptor tyrosine kinase system for cell-cell	 on specific tyrosine residues. In certain experimental settings,
signalling that is involved in organogenesis in nerve, muscle, 	 nearly all combinations of ErbB receptors appear to be
epithelia, and other tissues (Lemke, Mol. Cell. Neurosci. 7: 	 capable of forming dimers in response to the binding of
247-262, 1996 and Burden et al., Neuron 18: 847-855, 1997). 	 NRG-1 isoforms. However, it appears that ErbB2 is a pre-
The NRG family consists of three genes that encode numer- 45 ferred dimerization partner that may play an important role in
ous ligands containing epidermal growth factor (EGF)-like, 	 stabilizing the ligand-receptor complex. Recent evidence has
immunoglobulin (Ig), and other recognizable domains. At	 shown that expression of NRG-1, ErbB2, and ErbB4 is nec-
least 20 (perhaps 50 or more) secreted and membrane-at-	 essary for trabeculation of the ventricular myocardium during
tached isoforms may function as ligands in this signalling 	 mouse development.
system. The receptors for NRG ligands are all members of the 50 In view of the high prevalence of congestive heart failure in
EGF receptor (EGFR) family, and include EGFR (or ErbB 1), 	 the general population, it would be highly beneficial to pre-
ErbB2, ErbB3, and ErbB4, also known as HERI through 	 vent or minimize progression of this diseaseby inhibiting loss
HER4, respectively, in humans (Meyer et al., Development	 of cardiac function, and ideally, by improving cardiac func-
124: 3575-3586, 1997; Orr-Urtreger et al., Proc. Natl. Acad. 	 tion for those who have or are at risk for congestive heart
Sci. USA 90: 1867-71, 1993; Marchionni et al., Nature 362: 55 failure.
312-8, 1993; Chen et al., J. Comp. Neurol. 349: 389-400,
1994; Corfas et al., Neuron 14: 103-115, 1995; Meyer et al., 	 SUMMARY OF THE INVENTION
Proc. Natl. Acad. Sci. USA 91:1064-1068,1994; and Pinkas-
Kramarski et al., Oncogene 15: 2803-2815, 1997). 	 We have found that neuregulins stimulate compensatory
The three NRG genes, Nrg-1, Nrg-2, and Nrg-3, map to 6o hypertrophic growth and inhibit apoptosis of myocardiocytes
distinct chromosomal loci (Pinkas-Kramarski et al., Proc.	 subjected to physiological stress. Our observations indicate
Natl. Acad. Sci. USA 91: 9387-91, 1994; Carraway et al., 	 that neuregulin treatment will be useful for preventing, mini-
Nature 387: 512-516, 1997; Chang et al., Nature 387: 509-	 mizing, or reversing congestive heart disease resulting from
511, 1997; and Zhang et al., Proc. Natl. Acad. Sci. USA 94:	 underlying factors such as hypertension, ischemic heart dis-
9562-9567, 1997), and collectively encode a diverse array of 65 ease, and cardiotoxicity.
NRG proteins. The most thoroughly studied to date are the 	 The invention provides a method for treating or preventing
gene products of Nrg-1, which comprise a group of approxi- 	 congestive heart failure in a mammal. The method involves
US 7,662,772 B2
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administering a polypeptide that contains an epidermal
growth factor-like (EGF-like) domain to the mammal,
wherein the EGF-like domain is encoded by a neuregulin
gene, and wherein administration of the polypeptide is in an
amount effective to treat or prevent heart failure in the mam-
mal.
In various preferred embodiments of the invention, the
neuregulin gene may be the NRG-1 gene, the NRG-2 gene, or
the NRG-3 gene. Furthermore, the polypeptide may be
encoded by any of these three neuregulin genes. Still further,
the polypeptide used in the method may be recombinant
human GGF2.
In another preferred embodiment of the invention, the
mammal is a human.
In other embodiments of the invention, the congestive heart
failure may result from hypertension, ischemic heart disease,
exposure to a cardiotoxic compound (e.g., cocaine, alcohol,
an anti-ErbB2 antibody or anti-HER2 antibody, such as HER-
CEPTINO, or an anthracycline antibiotic, such as doxorubi-
cin or daunomycin), myocarditis, thyroid disease, viral infec-
tion, gingivitis, drug abuse; alcohol abuse, periocarditis,
atherosclerosis, vascular disease, hypertrophic cardiomyopa-
thy, acute myocardial infarction or previous myocardial inf-
arction, left ventricular systolic dysfunction, coronary bypass
surgery, starvation, an eating disorder, or a genetic defect.
In another embodiment of the invention, an anti-ErB2 or
anti-HER2 antibody, such as HERCEPTINO, is administered
to the mammal either before, during, or after anthracycline
administration.
In other embodiments of the invention, the polypeptide
containing an EGF-like domain encoded by a neuregulin gene
is administered before, during, or after exposure to a car-
diotoxic compound. In yet other embodiments, the polypep-
tide containing the EGF-like domain is administered during
two, or all three, of these periods.
In still other embodiments of the invention, the polypeptide
is administered either prior to or after the diagnosis of con-
gestive heart failure in the mammal.
In yet another embodiment of the invention, the polypep-
tide is administered to a mammal that has undergone com-
pensatory cardiac hypertrophy.
In other preferred embodiments of the invention, adminis-
tration of the polypeptide maintains left ventricular hypertro-
phy, prevents progression of myocardial thinning, or inhibits
cardiomyocyte apoptosis.
In yet another embodiment of the invention, the polypep-
tide may be administered by administering an expression
vector encoding the polypeptide to the mammal.
By "congestive heart failure" is meant impaired cardiac
function that renders the heart unable to maintain the normal
blood output at rest or with exercise, or to maintain a normal
cardiac output in the setting of normal cardiac filling pressure.
A left ventricular ejection fraction of about 40% or less is
indicative of congestive heart failure (by way of comparison,
an ejection fraction of about 60% percent is normal). Patients
in congestive heart failure display well-known clinical symp-
toms and signs, such as tachypnea, pleural effusions, fatigue
at rest or with exercise, contractile dysfunction, and edema.
Congestive heart failure is readily diagnosed by well known
methods (see, e.g., "Consensus recommendations for the
management of chronic heart failure." Am. J. Cardiol.,
83(2A):1A38-A, 1999).
Relative severity and disease progression are assessed
using well known methods, such as physical examination,
echocardiography, radionuclide imaging, invasive hemody-
4
namic monitoring, magnetic resonance angiography, and
exercise treadmill testing coupled with oxygen uptake stud-
ies.
By "ischemic heart disease" is meant any disorder result-
5 ing from an imbalance between the myocardial need for oxy-
gen and the adequacy of the oxygen supply. Most cases of
ischemic heart disease result from narrowing of the coronary
arteries, as occurs in atherosclerosis or other vascular disor-
ders.
10 By "myocardial infarction" is meant a process by which
ischemic disease results in a region of the myocardium being
replaced by scar tissue.
By "cardiotoxic" is meant a compound that decreases heart
function by directing or indirectly impairing or killing cardi-
15 omyocytes.
By "hypertension" is meant blood pressure that is consid-
ered by a medical professional (e.g., a physician or a nurse) to
be higher than normal and to carry an increased risk for
developing congestive heart failure.
20 By "treating" is meant that administration of a neuregulin
or neuregulin-like polypeptide slows or inhibits the progres-
sion of congestive heart failure during the treatment, relative
to the disease progression that would occur in the absence of
treatment, in a statistically significant manner. Well known
25 indicia such as left ventricular ejection fraction, exercise per-
formance, and other clinical tests as enumerated above, as
well as survival rates and hospitalization rates may be used to
assess disease progression. Whether or not a treatment slows
or inhibits disease progression in a statistically significant
30 manner may be determined by methods that are well known in
the art (see, e.g., SOLVD Investigators, N. Engl. J. Med.
327:685-691, 1992 and Cohn et al., N. Engl. J. Med. 339:
1810-1816, 1998).
By "preventing" is meant minimizing or partially or com-
35 pletely inhibiting the development of congestive heart failure
in a mammal at risk for developing congestive heart failure
(as defined in "Consensus recommendations for the manage-
ment of chronic heart failure." Am. J. Cardiol., 83(2A):
1A-38-A, 1999). Determination of whether congestive heart
40 failure is minimized or prevented by administration of a neu-
rgulin or neuregulin-like polypeptide is made by known
methods, such as those described in SOLVD Investigators,
supra, and Cohn et al., supra.
By "at risk for congestive heart failure" is meant an indi-
45 vidual who smokes, is obese (i.e., 20% or more over their
ideal weight), has been or will be exposed to a cardiotoxic
compound (such as an anthracycline antibiotic), or has (or
had) high blood pressure, ischemic heart disease, a myocar-
dial infarct, a genetic defect known to increase the risk of
5o heart failure, a family history of heart failure, myocardial
hypertrophy, hypertrophic cardiomyopathy, left ventricular
systolic dysfunction, coronary bypass surgery, vascular dis-
ease, atherosclerosis, alcoholism, periocarditis, a viral infec-
tion, gingivitis, or an eating disorder (e.g., anorexia nervosa
55 or bulimia), or is an alcoholic or cocaine addict.
By "decreasing progression of myocardial thinning" is
meant maintaining hypertrophy of ventricular cardiomyo-
cytes such that the thickness of the ventricular wall is main-
tained or increased.
60 By "inhibits myocardial apoptosis" is meant that neuregu-
lin treatment inhibits death of cardiomyocytes by at least
10%, more preferably by at least 15%, still more preferably
by at least 25%, even more preferably by at least 50%, yet
more preferably by at least 75%, and most preferably by at
65 least 90%, compared to untreated cardiomyocytes.
By "neuregulin" or "NRG" is meant a polypeptide that is
encoded by an NRG-1, NRG-2, or NRG-3 gene or nucleic
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acid (e.g., a cDNA), and binds to and activates ErbB2, ErbB3,
or ErbB4 receptors, or combinations thereof.
By "neuregulin-1," "NRG-1," "heregulin," "GGF2," or
11p185erbB2 ligand" is meant a polypeptide that binds to the
ErbB2 receptor and is encoded by the  I85erbB2 ligand gene
described in U.S. Pat. Nos. 5,530,109; 5,716,930; and U.S.
Ser. No. 08/461,097.
By "neuregulin-like polypeptide" is meant a polypeptide
that possesses an EGF-like domain encoded by a neuregulin
gene, and binds to and activates ErbB-2, ErbB-3, ErbB-4, or
a combination thereof.
By "epidermal growth factor-like domain" or "EGF-like
domain" is meant a polypeptide motif encodedby the NRG-1,
NRG-2, or NRG-3 gene that binds to and activates ErbB2,
ErbB3, ErbB4, or combinations thereof, andbears a structural
similarity to the EGF receptor-binding domain as disclosed in
Holmes et al., Science 256:1205-1210, 1992; U.S. Pat. Nos.
5,530,109; 5,716,930; U.S. Ser. No. 08/461,097; Hijazi et al.,
Int. J. Oncol. 13:1061-1067, 1998; Chang et al., Nature 387:
509-512, 1997; Carraway et al., Nature 387:512-516, 1997;
Higashiyama et al., J. Biochem. 122: 675-680,1997; and WO
97/09425).
By "anti-ErbB2 antibody" or "anti-HER2 antibody" is
meant an antibody that specifically binds to the extracellular
domain of the ErbB2 (also known as HER2 in humans) recep-
tor and prevents the ErbB2 (HER2)-dependent signal trans-
duction initiated by neuregulin binding.
By "transformed cell" is meant a cell (or a descendent of a
cell) into which a DNA molecule encoding a neuregulin or
polypeptide having a neuregulin EGF-like domain has been
introduced, by means of recombinant DNA techniques or
known gene therapy techniques.
By "promoter" is meant a minimal sequence sufficient to
direct transcription. Also included in the invention are those
promoter elements which are sufficient to render promoter-
dependent gene expression controllable for cell type orphysi-
ological status (e.g., hypoxic versus normoxic conditions), or
inducible by external signals or agents; such elements may be
located in the 5' or 3' or internal regions of the native gene.
By "operably linked" is meant that a nucleic acid encoding
a polypeptide (e.g., a cDNA) and one or more regulatory
sequences are connected in such a way as to permit gene
expression when the appropriate molecules (e.g., transcrip-
tional activator proteins) are bound to the regulatory
sequences.
By "expression vector" is meant a genetically engineered
plasmid or virus, derived from, for example, a bacteriophage,
adenovirus, retrovirus, poxvirus, herpesvirus, or artificial
chromosome, that is used to transfer a polypeptide (e.g., a
neuregulin) coding sequence, operably linked to a promoter,
into a host cell, such that the encoded peptide or polypeptide
is expressed within the host cell.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. lA is a representation of a semiquantitative RT-PCR
analysis showing expression of neuregulin receptors during
cardiac development and in adult rat cardiomyocytes.
FIG. 1B is a representation of an assay showing tyrosine
phosphorylation of the ErbB4 receptor in cardiomyocytes
treated with recombinant human glial growth factor 2
(rhGGF2).
FIGS. 2A and 2B are representations of photomicrographs
showing staining of neonatal rat ventricular myocytes for
myosin heavy chain (FIG. 2A) and BrdU-positive nuclei
(FIG. 2B).
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FIG. 2C is a graph showing that rhGGF2 stimulates DNA
synthesis (indicated by % BrdU-positive myocytes) in neo-
natal rat ventricular myocytes.
FIGS. 3A and 3B are graphs showing that rhGGF2 stimu-
5 lates DNA synthesis (indicated by % relative 3H-thymidine
uptake) in neonatal rat ventricular myocytes.
FIG. 4 is a graph showing that ErbB2 and ErbB4 mediate
the effects of GGF2 on relative 3H-thymidine uptake in neo-
natal rat ventricular myocytes.
10	 FIG. 5 is a graph showing that GGF2 promotes survival in
primary cultures of neonatal rat ventricular myocytes.
FIGS. 6A-6C and 6E-6G are representations of photomi-
crographs showing that GGF2 diminishes apoptotic cell
death in primary cultures of neonatal rat ventricular myo-
15 cytes.
FIG. 6D is a graph showing that rhGGF2 diminishes apo-
ptotic cell death in primary cultures of neonatal rat ventricular
myocytes (indicated by a decrease in the percentage of
TUNEL-positive myocytes).
20 FIG. 6H is a graph showing that rhGGF2 diminishes apo-
ptotic cell death in primary cultures of neonatal rat ventricular
myocytes (determined by flow cytometry analysis of the sub-
GI fraction following propidium iodide staining of rhGGF2-
treated cells).
25 FIGS. 7A and 7B are graphs showing that rhGGF2
increases survival and decreases apoptotic cell death in pri-
mary cultures of adult rat ventricular myocytes.
FIGS. 8A and 8B are representations of photomicrographs
showing that GGF2 induces hypertrophic growth of neonatal
3o rat ventricular myocytes.
FIG. 8C is a representation of a Northern blot showing that
prepro-atrial natriuretic factor (prepro-ANF), a marker of
ventricular hypertrophy, and a-skeletal actin are up-regulated
in neonatal rat ventricular myocytes treated with GGF2.
35 FIG. 8D is a graph showing that GGF2 stimulates protein
synthesis (indicated by relative 3 H-leucine uptake) in neona-
tal rat ventricular myocytes.
FIGS. 9A-9C are photomicrographs showing that GGF2
induces hypertrophic growth in primary cultures of adult rat
40 ventricular myocytes.
FIG. 9D is a representation of Northern blots showing that
prepro-ANF and a-skeletal actin are up-regulated in adult rat
ventricular myocytes treated with GGF2.
FIG. 9E is a graph showing that GGF2 stimulates protein
45 synthesis (indicatedby relative 3H-leucine uptake) in adult rat
ventricular myocytes.
FIGS. 10A and 10B are representations of ribonuclease
protection assays showing expression levels of ErbB2 (FIG.
10A), ErbB4 (FIG. 10B), and R -actin in the left ventricles of
50 control and aortic stenosis rat hearts.
FIG. 11 is a representation of a Northern blot showing
expression of ANF and glyceraldehyde phosphate dehydro-
genase (GAPDH, a housekeeping gene) in myocytes from left
ventricles of control and aortic stenosis rat hearts.
55 FIGS. 12A and 12B are representations of ribonuclease
protection assays showing expression levels of ErbB2 (FIG.
12A), ErbB4 (FIG. 12B), and R -actin in myocytes from the
left ventricles of control and aortic stenosis rat hearts.
FIGS. 13A and 13B are representations of a Western blot
60 showing expression levels of ErbB2 in 6-week (FIG. 13A)
and 22-week (FIG. 13B) aortic stenosis and control rathearts.
FIGS. 13C and 13D are representations of a Western blot
showing expression levels of ErbB2 in 6-week (FIG. 13C)
and 22-week (FIG. 13D) aortic stenosis and control rat hearts.
65 FIG. 14 is a graph showing that rat cardiomyocyte cultures
pre-treated with IGF-1 or NRG-1 are less susceptible to
daunorubicin-induced apoptosis.
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FIG. 15A is a representation of a phosphorylation assay
showing that IGF- and NRG-1-stimulated pho sphorylation of
Akt is inhibited by the PI-3 kinase inhibitor wortmannin.
FIG. 15B is a graph showing that IGF-1 and NRG-1 inhi-
bition of caspase 3 activation in cells exposed to daunorubicin
is PI-3 kinase-dependent.
DETAILED DESCRIPTION OF THE INVENTION
We have found that neuregulins promote survival and
hypertrophic growth of cultured cardiac myocytes through
activation of ErbB2 and ErbB4 receptors.
In addition, we have observed, in animals with experimen-
tally-induced intracardiac pressure overload, that cardiomyo-
cyte ErbB2 and ErbB4 levels are normal during early com-
pensatory hypertrophy and decrease during the transition to
early heart failure.
Together, our in vitro and in vivo findings show that neu-
regulins are involved in stimulating compensatory hyper-
trophic growth in response to increased physiologic stress, as
well as inhibiting apoptosis of myocardial cells subjected to
such stress. These observations indicate that neuregulin treat-
ment will be useful for preventing, minimizing, or reversing
congestive heart disease. While not wishing to be bound by
theory, it is likely that neuregulin treatment will strengthen
the pumping ability of the heart by stimulating cardiomyo-
cyte hypertrophy, and will partially or completely inhibit
further deterioration of the heart by suppressing cardiomyo-
cyte apoptosis.
Neuregulins
Polypeptides encoded by the NRG-1, NRG-2, and NRG-3
genes possess EGF-like domains that allow them to bind to
and activate ErbB receptors. Holmes et al. (Science 256:
1205-1210,1992) has shown that the EGF-like domain alone
is sufficient to bind and activate the p185erbB2 receptor.
Accordingly, any polypeptide product encoded by the NRG-
1, NRG-2, or NRG-3 gene, or any neuregulin-like polypep-
tide, e.g., a polypeptide having an EGF-like domain encoded
by a neuregulin gene or cDNA (e.g., an EGF-like domain
containing the NRG-1 peptide subdomains C-C/D or C-C/D',
as described in U.S. Pat. Nos. 5,530,109, 5,716,930, and U.S.
Ser. No. 08/461,097; or an EGF-like domain as disclosed in
WO 97/09425) may be used in the methods of the invention to
prevent or treat congestive heart failure.
Risk Factors
Risk factors that increase the likelihood of an individual's
developing congestive heart failure are well known. These
include, and are not limited to, smoking, obesity, high blood
pressure, ischemic heart disease, vascular disease, coronary
bypass surgery, myocardial infarction, left ventricular sys-
tolic dysfunction, exposure to cardiotoxic compounds (alco-
hol, drugs such as cocaine, and anthracycline antibiotics such
as doxorubicin, and daunorubicin), viral infection, pericardi-
tis, myocarditis, gingivitis, thyroid disease, genetic defects
known to increase the risk of heart failure (such as those
described in Bachinski and Roberts, Cardiol. Clin. 16:603-
610, 1998; Sin et al., Circulation 8:1022-1026, 1999; and
Arbustini et al., Heart 80:548-558, 1998), starvation, eating
disorders such as anorexia and bulimia, family history of
heart failure, and myocardial hypertrophy.
Accordingly, neuregulins may be administered to prevent
or decrease the rate of congestive heart disease progression in
those identified as being at risk. For example, neuregulin
administration to a patient in early compensatory hypertro-
phy may permit maintenance of the hypertrophic state and
may prevent the progression to heart failure. In addition,
8
those identified to be at risk, as defined above, may be given
cardioproctive neuregulin treatment prior to the development
of compensatory hypertrophy.
Neuregulin administration to cancer patients prior to and
5 during anthracycline chemotherapy or anthracycline/anti-
ErbB2 (anti-HER2) antibody (e.g., HERCEPTINO) combi-
nation therapy may prevent the patients' cardiomyocytes
from undergoing apoptosis, thereby preserving cardiac func-
tion. Patients who have already suffered cardiomyocyte loss
io may also derive benefit from neuregulin treatment, because
the remaining myocardial tissue will respond to neuregulin
exposure by displaying hypertrophic growth and increased
contractility.
15 Therapy
Neuregulins and polypeptides containing EGF-like
domains encoded by neuregulin genes may be administered
to patients or experimental animals with a pharmaceutically-
acceptable diluent, carrier, or excipient, in unit dosage form.
20 Conventional pharmaceutical practice may be employed to
provide suitable formulations or compositions to administer
such compositions to patients or experimental animals.
Although intravenous administration is preferred, any appro-
priate route of administration may be employed, for example,
parenteral, subcutaneous, intramuscular, intracranial, intraor-
25 bital, ophthalmic, intraventricular, intracapsular, intraspinal,
intracisternal, intraperitoneal, intranasal, aerosol, oral, or
topical (e.g., by applying an adhesive patch carrying a formu-
lation capable of crossing the dermis and entering the blood-
stream) administration. Therapeutic formulations may be in
so the form of liquid solutions or suspensions; for oral adminis-
tration, formulations may be in the form of tablets or cap-
sules; and for intranasal formulations, in the form of powders,
nasal drops, or aerosols. Any of the above formulations may
s5 be a sustained-release formulation.Methods well known in the art for making formulations are
found in, for example, "Remington's Pharmaceutical Sci-
ences." Formulations for parenteral administration may, for
example, contain excipients, sterile water, or saline, polyalky-
40 
lene glycols such as polyethylene glycol, oils of vegetable
origin, or hydrogenated napthalenes. Sustained-release, bio-
compatible, biodegradable lactide polymer, lactide/glycolide
copolymer, or polyoxyethylene-polyoxypropylene copoly-
mers may be used to control the release of the compounds.
45 Other potentially useful parenteral delivery systems for
administering molecules of the invention include ethylene-
vinyl acetate copolymer particles, osmotic pumps, implant-
able infusion systems, and liposomes. Formulations for inha-
lation may contain excipients, for example, lactose, or may be
aqueous solutions containing, for example, polyoxyethylene-
so 9-lauryl ether, glycocholate and deoxycholate, or may be oily
solutions for administration in the form of nasal drops, or as
a gel.
Gene Therapy
55 Neuregulins and neuregulin-like polypeptides containing
neuregulin EGF-like domains may also be administered by
somatic gene therapy. Expression vectors for neuregulin gene
therapy (e.g., plasmids, artificial chromosomes, or viral vec-
tors, such as those derived from adenovirus, retrovirus, pox-
60 virus, or herpesvirus) carry a neuregulin-encoding (or neu-
regulin-like polypeptide-encoding) DNA under the
transcriptional regulation of an appropriate promoter. The
promoter may be any non-tissue-specific promoter known in
the art (for example, an SV-40 or cytomegalovirus promoter).
65 Alternatively, the promoter may be a tissue-specific pro-
moter, such as a striated muscle-specific, an atrial or ventricu-
lar cardiomyocyte-specific (e.g., as described in Franz et al.,
US 7,662,772 B2
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Cardiovasc. Res. 35:560-566, 1997), or an endothelial cell-
specific promoter. The promoter may be an inducible pro-
moter, such as the ischemia-inducible promoter described in
Prentice et al. (Cardiovasc. Res. 35:567-574, 1997). The pro-
moter may also be an endogenous neuregulin promoter. 	 5
The expression vector may be administered as naked DNA
mixed with or conjugated to an agent to enhance the entry of
the DNA into cells, e.g., a cationic lipid such as LipofectinTM
LipofectamineTM (Gibco/BRL, Bethesda, Md.), DOTAPTM 10(Boeringer-Mannheim, Indianapolis, Ind.) or analogous
compounds, liposomes, or an antibody that targets the DNA
to a particular type of cell, e.g., a cardiomyocyte or an endot-
helial cell. The method of administration may be any of those
described in the Therapy section above. In particular, DNA 15
for somatic gene therapy has been successfully delivered to
the heart by intravenous injection, cardiac perfusion, and
direct injection into the myocardium (e.g., see Losordo et al.,
Circulation 98:2800-2804, 1998; Lin et al., Hypertension
33:219-224, 1999; Labhasetwar et al., J. Pharm. Sci. 20
87:1347-1350, 1998; Yayama et al., Hypertension 31:1104-
1110, 1998). The therapeutic DNA is administered such that
it enters the patient's cells and is expressed, and the vector-
encoded therapeutic polypeptide binds to and activates car-
diomyocyte ErbB receptors.	 25
The following Examples will assist those skilled in the art
to better understand the invention and its principles and
advantages. It is intended that these Examples be illustrative
of the invention and not limit the scope thereof. 	 30
EXAMPLE I
General Methods
35
Preparation of Cardiac Myocyte and Non-Myocyte Pri-
mary Cultures
Neonatal rat ventricular myocyte (NRVM) primary cul-
tures were prepared as described previously (Springhorn et 40
al., J. Biol. Chem. 267: 14360-14365, 1992). To selectively
enrich for myocytes, dissociated cells were centrifuged twice
at 500 rpm for 5 min, pre-plated twice for 75 min, and finally
plated at low density (0.7-1x104 cells/cm2) in Dulbecco's
modified Eagle's (DME) medium (Life Technologies Inc., 45
Gaithersburg, Md.) supplemented with 7% fetal bovine
serum (FBS) (Sigma, St. Louis, Mo.). Cytosine arabinoside
(AraC; 10 µM; Sigma) was added to cultures during the first
24-48 h to prevent proliferation of non-myocytes, with the
exception of cultures used for thymidine uptake measure- 50
ments. Unless otherwise stated, all experiments were per-
formed 36-48 h after changing to a serum-free medium, DME
plus ITS (insulin, transferrin, and selenium; Sigma). Using
this method, we routinely obtained primary cultures with
>95% myocytes, as assessed by microscopic observation of 55
spontaneous contraction and by immunofluorescence stain-
ing with a monoclonal anti-cardiac myosin heavy chain anti-
body (anti-MHC; Biogenesis, Sandown, N.H.).
Primary cultures of cellular fractions isolated from neona- 60
tal hearts enriched in non-myocyte cells were prepared by
twice passaging cells that adhered to the tissue culture dish
during the preplating procedure. These non-myocyte cul-
tures, which contained few anti-MHC-positive cells, were
allowed to grow to subconfluence in DME supplemented with 65
20% FBS before switching to DME-ITS for a subsequent 36
to 48 h.
10
Isolation and preparation of adult rat ventricular myocyte
(ARVM) primary cultures was carried out using techniques
previously described (Berger et al., Am. J. Physiol. 266:
H341-H349,1994). Rod-shaped cardiac myocytes were
plated in culture medium on laminin (10 µg/ml; Collabora-
tive Research, Bedford, Mass.) precoated dishes for 60 min,
followed by one change of medium to remove loosely
attached cells. The contamination ofARVM primary cultures
by non-myocytes was determined by counting with a
haemocytometer and was typically less than 5%. All ARVM
primary cultures were maintained in a defined medium
termed "ACCITT" (Ellingsen et al., Am. J. Physiol. 265:
H747-H754,1993) composed of DME, supplemented with 2
mg/ml BSA, 2 mM L-camitine, 5 mM creatine, 5 mM taurine,
0.1 µM insulin, and 10 nM triiodothyronine with 100 IU/ml
penicillin and 100 µg/ml streptomycin. In experimental pro-
tocols designed to examine myocyte survival and/or apopto-
sis, insulin was omitted from the defined medium, which is
therefore termed "ACCTT".
PCR Analysis of ErbB Receptors in Rat Heart
cDNA sequences encoding portions of the C-termini of
ErbB receptors were amplified by using the following syn-
thetic oligonucleotide primers: ErbB2A (5'-TGTGCTAGT-
CAAGAGTCCCAACCAC-3': sense; SEQ ID NO: 1) and
ErbB2B (5'-CCTTCTCTCGGTAC TAAGTATTCAG-3':
antisense; SEQ ID NO: 2) for amplification of ErbB2 codon
positions 857 to 1207 (Bargmann et al., Nature 319: 226-230,
1986); ErbB3A (5'-GCTTAAAGTGCTTGGCTCGGGT-
GTC-3': sense; SEQ ID NO: 3) and ErbB3B (5'-TCCTACA-
CACTGACACTTTCTCTT-3': antisense; SEQ ID NO: 4) for
amplification of ErbB3 codon positions 712 to 1085 (Kraus et
al., Proc. Natl. Acad. Sci. USA 86: 9193-9197, 1989);
ErbB4A (5'-AATTCACCCATCAGAGTGACGTTTGG-3':
sense; SEQ ID NO: 5) and ErbB4B (5'-TCCTGCAGG-
TAGTCTGGGTGCTG: antisense; SEQ IDNO: 6) for ampli-
fication of ErbB4 codon positions 896 to 1262 (Plowman et
al., Proc. Natl. Acad. Sci. USA 90: 1746-1750, 1993). RNA
samples (1 µg) from rat hearts or freshly isolated neonatal and
adult rat ventricular myocytes were reverse-transcribed to
generate first-strand cDNA. The PCR reactions were per-
formed in a final volume of 50 µl containing approximately 50
ng of first-strand cDNAs for thirty cycles in a PTC-100TM
Programmable Thermal Controller (M7 Research, Inc.;
Watertown, Mass.). Each cycle included 30 sec at 94° C., 75
sec at 63° C., and 120 sec at 72° C. Thirty µl aliquots of each
reaction mixture were analyzed by electrophoresis in 1%
agarose gels and by ethidium bromide staining. The PCR
products were directly cloned into the TA cloning vector
(Invitrogen Co., San Diego, Calif.) and verified by automatic
DNA sequencing.
Analysis of ErbB Receptor Phosphorylation
To analyze which receptor subtypes were tyrosine-phos-
phorylated, neonatal and adult ventricular myocyte cells were
maintained in serum-free medium for 24 to 48 h, and then
treated with recombinant human glial growth factor 2
(rhGGF2) at 20 ng/ml for 5 min at 37° C. Cells were quickly
rinsed twice with ice-cold phosphate-buffered saline (PBS)
and lysed in cold lysis buffer containing 1% NP40, 50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM ethylene glycol-bis
((3-aminoethyl ether)-N, N, N', N'-tetraacetic acid (EGTA), 1
mM ethylenediaminetetraacetic acid (EDTA), 0.5% sodium
deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 10
mM sodium molybdate, 8.8 g/L sodium pyrophosphate, 4 g/L
NaFl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10
µg/ml aprotinin, and 20 µM leupeptin. Lysates were centri-
fuged at 12,000xg at 4° C. for 20 min, and aliquots of 500 µg
(neonatal myocytes) or 2000 µg (adult myocytes) of superna-
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tant were incubated with antibody specific to ErbB2 or ErbB4
(Santa Cruz Biotechnology Inc., Santa Cruz, Calif.) over-
night at 4° C. and precipitated with protein A-agarose (Santa
Cruz Biotechnology, Inc.). Immunoprecipitates were col-
lected and released by boiling in sodium dodecyl sulfate
(SDS) sample buffer. Samples were fractionated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred
to polyvinylidene difluoride (PVDF) membranes (Biorad
Laboratories, Hercules, Calif.) and probed with a PY20
antiphosphotyrosine antibody (Santa Cruz Biotechnology,
Inc.). For detection of ErbB2, the supernatants were also
immunoprecipitated with a biotinylated RC20 antiphospho-
tyrosine antibody (Upstate Biotechnology, Inc., Lake Placid,
N.Y.) and blotted with a monoclonal antibody to ErbB2 (Ab-
2; Oncogene Research Products, Cambridge, Mass.).
Incorporation of [ 3H]Thymidine and [3H]Leucine
As an index of DNA synthesis, [ 3H]thymidine incorpora-
tion was measured as described previously (Berk et al.,
Hypertension 13:305-314, 1989). After incubation for 36 to
48 h in serum-free medium (DME plus ITS), the cells were
stimulated with different concentrations of rhGGF2 (Cam-
bridge NeuroScience Co., Cambridge, Mass.) for 20 h. [3H]
thymidine (0.7 Ci/mmol; Dupont) was then added to the
medium at a concentration of 5 µCi/ml and the cells were
cultured for another 8 h. Cells were washed with PBS twice,
10% TCA once, and 10% TCA was added to precipitate
protein at 4° C. for 45 min. Parallel cultures of myocytes not
exposed to rhGGF2 were harvested under the same condi-
tions as controls. The precipitate was washed twice with 95%
ethanol, resuspended in 0.15 N NaOH and saturated with 1 M
HCl, then aliquots were counted in a scintillation counter. The
results are expressed as relative cpm/dish normalized to the
mean cpm of control cells in each experiment. For antibody
blocking experiments, the same procedure was applied
except that the cells were preincubated with an antibody (0.5
g/ml) specific for each neuregulin receptor (c-neu Ab-2,
Oncogene Research Products; and ErbB3 or ErbB4, Santa
Cruz Biotechnology), for 2 h prior to addition of either
rhGGF2 or rhFGF2.
The rate of [3H]leucine uptake was used as an index of
protein synthesis. For these experiments, 10 µM cytosine
arabinoside was added to the culture medium. Cells were
grown in serum-free medium for 36 to 48 h and then stimu-
lated with different doses of rhGGF2. After 40 h, [3H]leucine
(5 µCi/ml) was added for 8 h, and cells were washed with PBS
and harvested with 10% TCA. TCA-precipitable radioactiv-
ity was determined by scintillation counting as above.
5-Bromo-2'-Deoxy-Uridine Incorporation and Immunof-
luorescence Staining
Nuclear 5-bromo-2'-deoxy-uridine (BrdU) incorporation
and a cardiac muscle-specific antigen, myosin heavy chain
(MHC), were simultaneously visualized using double-indi-
rect immunofluorescence. Primary NRVM cultures were
maintained in DME plus ITS for 48 h and then stimulated
with rhGGF2 (40 ng/ml) for 30 h. Control cultures were
prepared similarly but without rhGGF2. BrdU (10 µM) was
added for the last 24 h. Cells were fixed in a solution of 70%
ethanol in 50 mM glycine buffer, pH 2.0, for 30 min at —20°
C., rehydrated in PBS and incubated in 4 N HCl for 20 min.
Cells were then neutralized with three washes in PBS, incu-
bated with 1% FBS for 15 min, followed by a mouse mono-
clonal anti-MHC (1:300; Biogenesis, Sandown, N.H.) for 60
min at 37° C. The primary antibody was detected with
TRITC-conjugated goat anti-mouse IgG (1:300, The Jackson
Laboratory, Bar Harbor, Me.), and nuclear BrdU incorpora-
tion was detected with fluorescein-conjugated anti-BrdU
antibody from an in situ cell proliferation kit (Boehringer
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Mannheim Co. Indianapolis, Ind.). The coverslips were
mounted with Flu-mount (Fisher Scientific; Pittsburgh, Pa.),
and examined by immunofluorescence microscopy. About
500 myocytes were counted in each coverslip and the per-
5 centage of BrdU-positive myocytes was calculated.
For examination of changes in myocyte phenotype with
rhGGF2, cells were fixed in 4% (w/v) paraformaldehyde for
30 min at room temperature, rinsed with PBS, permeabilized
with 0.1 % Triton X-100 for 15 min, and then incubated with
10 1% FBS for another 15 min, followed by incubation with
anti-MHC (1:300) and visualized with TRITC-conjugated
(NRVM) or FITC-conjugated (ARVM) second antibody.
ARVM were examined using a MRC 600 confocal micro-
scope (BioRad; Hercules, Calif.) with a Kr/Ar laser.
15	 Cell Survival Assay and Detection of Apoptosis
Cell viability was determined by the 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma)
cell respiration assay, which is dependent on mitochondrial
activity in living cells (Mosman, J. Immunol. Meth. 65:55-63,
20 1983). Primary cultures of NRVM after 2 days in serum-free
medium were stimulated with different concentrations of
rhGGF2 for either 4 or 6 days. ARVM were maintained in
ACCTT medium or ACCTT medium plus different concen-
trations of rhGGF2 for 6 days. MTT was then incubated with
25 the cells for 3 h at 37° C. Living cells transform the tetrazo-
lium ring into dark blue formazan crystals that can be quan-
tified by reading the optical density at 570 nm after cell lysis
with dimethylsulfoxide (DMSO; Sigma).
30 Apoptosis was detected in neonatal and adult myocytes
using the terminal deoxynucleotidyltransferase (TdT)-medi-
ated dUTP nick end-labeling (TUNEL) assay. 3'-end label-
ling of DNA with fluorescein-conjugated dUTP was done
using an in situ cell death detection kit (Boehringer Man-
35 nheim, Indianapolis, Ind.) following the manufacturer'sinstructions. Cells were counterstained with an anti-MHC
antibody as described above, and the nuclei were also stained
with Hoescht 33258 (10 µM, Sigma) for 5 min. More than 500
myocytes were counted in each coverslip and the percentage
40 of TUNEL positive myocytes was calculated.
Flow cytometric analysis of neonatal myocytes fixed in
70% ethanol/PBS and stained withpropidium iodide was also
performed to quantify the percentage of cells undergoing
apoptosis. This method is based upon the observation that
45 cells undergoing apoptosis have a hypo-diploid quantity of
DNA and localize in a broad area below the GO/GI peak on a
DNA histogram. Briefly, cells were collected by trypsiniza-
tion, pooled with nonattached cells, and fixed in 70% ethanol.
After being rinsed once with PBS, cells were incubated with
50 a propidium iodide (20 µg/ml, Sigma) solution containing
RNase A (5 Kunitz units/ml) at room temperature for 30 min.
Data were collected using a FACScan (Becton-Dickinson,
San Jose, Calif.). For each sample, 10,000 events were col-
lected. Aggregated cells and extremely small cellular debris
55 were gated out.
Isolation and Hybridization of RNA
Total cellular RNA was isolated by a modification of the
acid guanidinium/thiocyanate phenol/chloroform extraction
method (Chomczynski and Sacchi, Anal. Biochem. 162:156-
60 159, 1987) using the TRIZOL reagent (Life Technologies
Inc., Gaithersburg, Md.). RNA was size-fractionated by
formaldehyde agarose gel electrophoresis, transferred to
nylon filters (Dupont, Boston, Mass.) by overnight capillary
blotting and hybridized with cDNA probes labelled with
65 [a 32P]dCTP by random priming (Life Technologies Inc.).
The filters were washed under stringent conditions and
exposed to X-ray film (Kodak X-OmatAR, Rochester, N.Y.).
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Signal intensity was determined by densitometry (Ultrascan
XL, Pharmacia). The following cDNA probes were used: rat
prepro-atrial natriuretic factor (prepro-ANF; a marker of car-
diomyocyte hypertrophy) (0.6 kb of coding region)
(Seidman, et al., Science 225:324-326, 1984), and rat skeletal
a-actin (240 by of a 3'-untranslated region) (Shan et al.,
Nucleic Acids Res. 9:579-589, 1981). A rat glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; a housekeeping gene)
cDNA probe (240 by of the coding region) (Tso et al., Nucleic
Acids Res. 13:2485-2502, 1985) was used as control for load-
ing and transfer efficiency.
Aortic Stenosis Model
Ascending aortic stenosis was performed in male Wistar
weaning rats (body weight 50-70 g, 3-4 weeks, obtained
from Charles River Breeding Laboratories, Wilmington,
Mass.), as previously described (Schunkert et al., Circulation,
87:1328-1339, 1993; Weinberg et al. Circulation, 90:1410-
1422, 1994; Feldman et al., Circ. Res., 73:184-192, 1993;
Schunkert et al., J. Clin. Invest. 96:2768-2774, 1995; Wein-
berg et al., Circulation, 95:1592-1600, 1997; Litwin et al.,
Circulation, 91:2642-2654; 1995). Sham-operated animals
served as age-matched controls. Aortic stenosis animals and
age-matched sham-operated controls were sacrificed after
anesthesia with intraperitoneal pentobarbital 65 mg/kg at 6
and 22 weeks after surgery (n=20-29 per group). Hemody-
namic and echocardiographic studies in this model have
shown that compensatory hypertrophy with normal left ven-
tricular (LU) cavity dimensions and contractile indices is
present 6 weeks after banding, whereas animals develop early
failure by 22 weeks after banding, which is characterized by
onset of LU cavity enlargement and mild depression of ejec-
tion indices and pressure development per gram LU mass. In
the present study, in vivo LU pressure measurements were
performed prior to sacrifice as previously described
(Schunkert et al., Circulation, 87:1328-1339,1993; Weinberg
et al. Circulation, 90:1410-1422, 1994; Feldman et al., Circ.
Res., 73:184-192, 1993; Schunkert et al., J. Clin. Invest.
96:2768-2774, 1995; Weinberg et al., Circulation, 95:1592-
1600, 1997; Litwin et al., Circulation, 91:2642-2654; 1995).
The animals were also inspected for clinical markers of heart
failure, including the presence of tachypnea, ascites, and
pleural effusions. Both body weight and LU weight were
recorded.
LU Myocyte Isolation for RNA Extraction
In a subset of animals (n=10 per group), the heart was
rapidly excised and attached to an aortic cannula. Myocyte
dissociation by collagenase perfusion was performed as pre-
viously described (Kagaya et al., Circulation, 94:2915-2922,
1996; Ito et al., J. Clin. Invest. 99:125-135, 1997; Tajima et
al., Circulation, 99:127-135, 1999). To evaluate the percent-
age of myocytes in the final cell suspension, aliquots of myo-
cytes were fixed, permeabilized and blocked. The cell sus-
pension was then incubated with antibodies against
a-sarcomeric actin (mAb, Sigma, 1:20) and von Willebrand
Factor (pAb, Sigma, 1:200) to distinguish between myocytes
and endothelial cells. Secondary antibodies (goat anti-rabbit,
goat anti-mouse pAb, Molecular probes, 1:400) with a Texas
Red (or Oregon Green) conjugate were used as a detection
system. Ninety-eight percent myocytes and less than 2% frag-
ments of endothelial cells or unstained cells (fibroblasts) were
routinely obtained.
RNA Analysis
Total RNA was isolated from control and hypertrophied
myocytes (n=10 hearts in each group), and from LU tissue
(n10 hearts in each group) using TRI Reagent (Sigma).
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Tissue and myocyte RNA were used for the following proto-
cols. Using myocyte RNA, Northernblots were used to assess
message levels of atrial natriuretic peptide which were nor-
malized to GAPDH (Feldman et al., Circ. Res. 73:184-192,
5 1993; Tajima et al., Circulation, 99:127-135, 1999). These
experiments were done to confirm the specificity of myocyte
origin of the RNA using this molecular marker of hypertro-
phy.
We also performed reverse transcription-polymerase chain
10 reactions (RT-PCRs) for initial estimation of the presence of
ErbB2, ErbB4 and neuregulin in samples derived from adult
rat heart and adult myocytes using the following pairs of
primers: ErbB2 sense 5' GCT GGC TCC GAT GTA TTT GAT
GGT 3' (SEQ ID NO: 7), ErbB2 antisense 5' GTT CTC TGC
15 CGT AGG TGT CCC TTT 3' (SEQ ID NO: 8) (Sarkar et al.,
Diagn. Mol. Pathol. 2:210-218, 1993); ErbB3 sense 5' GCT
TAA AGT GCT TGG CTC GGG TGT C 3' (SEQ ID NO: 3),
ErbB3 antisense 5' TCC TACACA CTGACA CTT TCT CTT
3' (SEQ ID NO: 4) (Kraus et al., Proc. Natl. Acad. Sci. USA
20 86:9193-9197; 1989), ErbB4 sense 5' AAT TCA CCC ATC
AGA GTG ACG TTT GG 3' (SEQ ID NO: 5), ErbB4 anti-
sense 5' TCC TGCAGG TAG TCT GGG TGC TG 3' (SEQ ID
NO: 6) (Plowman et al., Proc. Natl. Acad. Sci. USA 90:1746-
1750; 1993); neuregulin sense 5' GCA TCA CTG GCT GAT
25 TCT GGA G 3' (SEQ ID NO: 9), neuregulin antisense 5' CAC
ATG CCG GTT ATG GTC AGC A 3' (SEQ ID NO: 10). The
latter primers recognize nucleic acids encoded by the NRG-1
gene, but do not discriminate between its isoforms. The
amplification was initiated by 1 min of denaturation, 2 min of
30 annealing at the gene specific temperature and 2 min exten-
sion at 72° C. The whole PCR reaction was electrophoresed
on a 1% agarose gel and the PCR products of expected size
were gel-purified.
After cloning these fragments into pGEM-T vector
35 (Promega, Madison, Wis.), the correctness and orientation of
those fragments within the vector was confirmed by sequenc-
ing. Cloned PCR fragments were used to generate a radiola-
beled riboprobe using the MAXIscript in vitro transcription
kit (Ambion, Inc., Austin, Tex.) and a- 32P-UTP. Theplasmids
40 containing the ErbB2, ErbB4 or neuregulin fragment were
linearized and a radiolabeled probe was synthesized by in
vitro transcription with T7 or T3 RNA polymerase. The R -ac-
tin probe provided by the kit was transcribed with T7 or T3
polymerase and resulted in a 330 and 300 by fragment,
45 respectively. 20 µg of total RNA was hybridized to 5x 10 5 cpm
of ErbB2, ErbB4 or neuregulin c-RNA together with 2x104
cpm of R -actin for later normalization according to the RPA II
kit (Ambion) protocol.
After digestion with RNase A/RNase TI, the samples were
50 precipitated, dried, redissolved and finally separated on a 5%
polyacrylamide gel for 2 hours. The gel was exposed to
Kodak MR film for 12-48 hours, and the assay was quantified
by densitometric scanning of the auto-radiograph using
Image Quant software (Molecular Dynamics, Inc., Sunny-
55 vale, Calif.). ErbB2, ErbB4 and neuregulin mRNA levels
were normalized to (3-actin.
Western Blotting of ErbB2 and ErbB4
LU tissue (n=5 hearts per group) was rapidly homogenized
60 in a RIPA buffer containing 50 mmol/L Tris HCl, pH 7.4, 1 %
NP-40, 0.1 % SDS, 0.25% Na-deoxycholate, 150 mM NaCl, l
mM EDTA, 1 mM PMSF, 1 µg/ml Aprotinn, 1 µg/ml leupep-
tin, 1 µg/ml pepstatin and 1 mM Na3PO4. Proteins were
quantified using the Lowry assay kit (Sigma). 50 µg of protein
65 in Laemmli SDS sample buffer were boiled for 5 minutes and
after centrifugation loaded onto a 10% SDS-PAGE gel. After
electrophoresis, proteins were transferred to a nitrocellulose
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membrane at 100 mA overnight. The filters were blocked
with 0.05% Tween-20, 5% nonfat milk and then incubated
with anti-ErbB2 or anti-ErbB4 (Santa Cruz Biotechnology,
each diluted 1:100, 1 µg/ml). After incubation with goat anti-
rabbit peroxidase-conjugated secondary antibody diluted
1:2000, blots were subjected to the enhanced chemilumines-
cent (ECL) detection method (Amersham, Life Science) and
afterwards exposed to Kodak MR film for 30-180 seconds.
Protein levels were normalized to protein levels of R -actin
detected with anti-p-actin (Sigma).
In Situ Hybridization for Neuregulin
10-µm cryostat sections of left ventricular tissue (n=2 con-
trol and 6-week aortic stenosis hearts) were used for in situ
hybridizations. Antisense and sense RNA probe was synthe-
sized from cDNA fragments in pBluescript with either T7 or
T3 RNA polymerase and digoxigenin-labeled UTP (DIG
RNA Labeling Mix, Boehringer Mannheim). Tissue sections
were first treated with 4% paraformaldehyde for 20 minutes,
followed by 30 minutes digestion with proteinase K (10
µg/ml) at 37° C. and another 5 minutes of fixation in 4%
paraformaldehyde.
Following the fixation, the slides were washed in PBS three
times for 5 minutes, after which the sections were immersed
in 0.1 M triethanolamine chloride buffer with 0.25% acetic
anhydride for 10 minutes to block polar and charged groups
on the section and hence prevent nonspecific probe binding.
After washing the slides in 2xSSC, they were then prehybrid-
ized (50%formamide, 2xSSC, 5% dextransulfate, 0.1% SDS,
1 x Denhardt's, 400 µg/ml denatured salmon sperm DNA) at
45° C. for 60 minutes in a moist chamber charged with 50%
formamide/2xSSC. After 1 hour, the probes were addedto the
prehybridization solution and the slides were hybridized for
16-18 hours at 45° C.
Following overnight hybridization, slides were twice
washed in 4xSSC for 30 minutes at 45° C. while shaking, and
then incubated with RNaseA (40 µg/ml) in 500 mM NaCl, 10
mM Tris, 1 mM EDTA, pH 8.0, for 30 minutes at 37° C. to
remove unhybridized probe. After RNase treatment, sections
were immersed in 2xSSC at 50° C. for 30 minutes and then in
0.2xSSC at the same temperature for another 30 minutes. The
slides were equilibrated with TBS I buffer (100 mM Tris, 150
mM NaCl, pH 7.5) and then blocked with blocking reagent
for 30 minutes at room temperature according to the manu-
facturer's protocol (DIG Nucleic Acid Detection Kit, Boe-
hringer Mannheim).
After removing the blocking reagent, the slides were
immersed in TBS I for 1 minute and then the anti-DIG-AP
conjugate solution (DIG Nucleic Acid Detection Kit, Boe-
hringer Mannheim) was applied to each section for 1.5 hours
at room temperature in a humid chamber. Afterwards, the
slides were washed in TBS I three times, 10 minutes per wash,
to wash off the excess antibody and equilibrated in TBS II
(100 mM Tris, 100 mM NaCl, pH 9.5, 50 mM MgC12.7H2O)
for 5 minutes. The color substrate was prepared according to
the manufacturer's instructions and applied to each section
until a blue-colored reaction became visible. The reaction
was stopped and the slides were washed in PBS and distilled
water for 5 minutes each. After a nuclear counter-staining the
sections were dehydrated through an ethanol series,
immersed in xylene and mounted by cover-slipping in Per-
mount.
Statistical Analysis
All values are expressed as mean±SEM. Statistical analy-
sis of differences observed between the aortic stenosis groups
(6 and 22 weeks after banding) and the age-matched control
groups was done by ANOVA comparison. An unpaired Stu-
16
dent's test was used for comparison among the groups at the
same age post-banding. Statistical significance was accepted
at the level of p<0.05.
5	 EXAMPLE II
Neuregulins Promote Survival and Growth of
Cardiac Myocytes
io
Expression of Neuregulin Receptors in the Heart
To determine which of the NRG receptors (i.e., ErbB2,
ErbB3, ErbB4) are expressed in rat myocardium, RNA from
rat heart tissues at successive stages of development, and
15 from freshly isolated neonatal and adult ventricular myo-
cytes, were reverse-transcribed and amplified by PCR, using
primers that flank the variable C-termini of ErbB receptors.
FIG. lA shows the semiquantitative RT-PCR analysis of neu-
regulin receptor mRNA levels during cardiac development.
20 Total RNA from embryonic (E14, E16, and E19), neonatal
(P 1) or adult (Ad) rat heart, and from freshly isolated neonatal
rat ventricular myocytes (NRVM) or adult rat ventricular
myocytes (ARVM) was reverse-transcribed into cDNA and
25 amplified with receptor isofonn-specific primers (see Meth-
ods). GAPDH was used as a control for reverse transcription,
PCR amplification, and gel loading ("M" denotes 1 kb or 120
by DNA molecular weight standards). The RT-PCR products
were verified by DNA sequencing.
30 All three ErbB receptors were expressed in the developing
rat heart at mid-embryogenesis (E14), with the following
rank order of their relative mRNA abundances:
ErbB4>ErbB2>ErbB3. The expression of ErbB receptors
was down-regulated later in embryogenesis. At El 6 and El 9,
35 and at post-natal day 1 (PI), only ErbB2 and ErbB4 mRNAs
could be detected. In adult rat heart, ErbB4 was still detect-
able, but its mRNA abundance was lower than that detected in
embryonic and neonatal hearts, whereas ErbB2 mRNA and,
40 
rarely, ErbB3 mRNA could be detected only at low levels in
adult myocardium. In freshly isolated neonatal and adult rat
ventricular myocyte primary cultures, both ErbB2 and ErbB4
mRNA were readily detectable by RT-PCR, although ErbB4
expression levels were consistently higher than those of
45 ErbB2. Furthermore, when using receptor-specific cDNA
probes for ErbB2, ErbB3 and ErbB4, only transcripts for
ErbB4 were readily detectable in freshly isolated neonatal
and adult rat ventricular myocytes by Northern blot.
To determine which of the ErbB receptors were tyrosine-
50 phosphorylated following neuregulin treatment, primary cul-
tures of NRVM or ARVM, maintained in serum-free medium
for 24 to 48 h, were treated either with or without neuregulin,
i.e., recombinant human glial growth factor 2 (rhGGF2) (20
ng/ml) for 5 min. ErbB4 receptor protein was immunopre-
55 cipitated with an anti-ErbB4 antibody from 500 µg of NRVM
lysates or 2000 µg of ARVM lysates, and phosphorylated
form of ErbB4 was detected by an anti -phosphotyrosine anti-
body. The blot shown in FIG. 1B is representative of 3 inde-
pendent experiments. As shown in FIG. 113, phosphorylated
6o ErbB4 is quite prominent in neonatal myocytes and less
robust, but detectable, in adult myocytes, which is consistent
with the levels of ErbB4 mRNA abundance we observed
above. Phosphorylated forms of ErbB2 and ErbB3 could not
be detected even if immunoprecipitated with biotinylated-
65 antipho sphotyro sine antibody, consistent with the much-re-
duced mRNA abundances for these two neuregulin receptors
in post-natal cardiac myocytes.
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GGF2 Stimulates DNA Synthesis in Neonatal Rat Ven-
tricular Myocytes
To investigate the ability of GGF2 to stimulate DNA syn-
thesis in NRVM primary cultures, myocytes maintained in
serum-free medium for 2 days were subsequently treated with
40 ng/ml rhGGF2 for 30 h. DNA synthesis was monitored by
measuring the incorporation of either BrdU (FIG. 213) or
[3H]thymidine (FIGS. 3A and 313), which were added to the
media either 24 h or 8 h, respectively, before termination of
each experiment.
FIG. 2A shows myocyte myosin heavy chain in NRVM,
visualized with a TRITC-conjugated goat anti-mouse anti-
body (red). FIG. 2B shows BrdU-positive nuclei visualized
with a fluorescein-conjugated mouse anti-BrdU antibody
(green). The scale bar for FIGS. 2A and 2B is equilvalent to
10 µm. FIG. 2C shows the percentage of BrdU-positive myo-
cytes under control conditions and in the presence of GGF2
(data are mean±SD for 3 experiments. *, p<0.01). As dis-
played in FIG. 2C, 40 ng/ml (approximately 0.7 nM) of
rhGGF2 increased the percentage of BrdU-labelled myocytes
(from postnatal day 1 rat heart ventricles) by about 80%, an
increase in magnitude that was similar to that observed with
[3H]thymidine incorporation (FIG. 3A).
FIGS. 3A and 3B show the effects of GGF2 on DNA
synthesis in myocyte-enriched and non-myocyte fractions
from rat ventricular myocyte primary isolates. In FIG. 3A,
NRVM-enriched primary isolates or a "non-myocyte"-en-
riched fraction (see Methods) were exposed to control (i.e.,
serum-free) medium alone (Ctl) or to medium containing
either 40 ng/ml rhGGF2 (GGF) or 7% fetal bovine serum
(FBS). In FIG. 313, concentration-dependent effect of GGF2
on NRVM DNA synthesis is shown. DNA synthesis was
assessed by [3H]thymidine incorporation, and the data are
expressed as relative cpm/dish normalized to the mean cpm of
control cells in each experiment (mean±SD of triplicate
analyses from three independent experiments; *, p<0.01 vs
control). Twenty ng/ml of rhGGF2 provoked an approximate
60% increase in [3H]thymidine incorporation into NRVM,
which was about half that observed with 7% FBS. The mito-
genic effect of rhGGF2 on NRVM was concentration-depen-
dent, with about an 80% increase at 50 ng/ml (i.e., 0.9 nM)
(FIG. 313). GGF2 had similar mitogenic effects on BrdU or
[3H]thymidine incorporation on rat embryonic ventricular
myocytes (E19) and postnatal ventricular myocytes (P5),
whereas concentrations of GGF2 as high as 100 ng/ml had no
effect on DNA synthesis in adult rat ventricular myocyte
primary cultures.
The effects of rhGGF2 on non-myocyte fractions obtained
following the preplating steps of the neonatal rat ventricular
myocyte isolation procedure also were investigated. As
shown in FIG. 3A, rhGGF2 did not induce any significant
change in [3H]thymidine incorporation into non-myocytes.
This was in contrast to 7% FBS, which induced nearly a
10-fold increase in [3 H]thymidine incorporation into this cell
population. Therefore, GGF2 shows a relatively specific
action on cardiac myocytes compared to a myocyte-depleted
cell population which, using the method of myocyte isolation
we employed here, is composed largely of fibroblasts and
endothelial cells.
To determine which of the known neuregulin receptors
mediate the mitogenic effect of GGF2 on fetal and neonatal
ventricular myocytes, DNA synthesis was measured in pri-
mary NRVM cultures after incubation with antibodies spe-
cific for ErbB2, ErbB3 and ErbB4. Neonatal myocytes were
cultured for two days in serum-free medium, after which they
were treated for 30 h either without (control), or with rhGGF2
(10 ng/ml), or with rhFGF2 (20 ng/ml), or with GGF2/FGF2
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and antibodies to ErbB2, ErbB3 or ErbB4, either alone or in
combination as illustrated. Antibodies (0.5 µg/ml/antibody)
were preincubated with cells for 2 h before the addition of
either GGF2 or FGF2. [3 H]Thymidine was added during the
5 last 8 h (data are expressed as relative cpm/dish normalized to
the mean cpm of control cells in each experiment, and are
presented as mean±SD; n=3 independent experiments; *,
p<0.04 vs rhGGF2 alone; #, p>0.1 vs rhGGF2 alone).
10 As shown in FIG. 4, a monoclonal antibody against the
extracellular domain of c-neu/ErbB2, inhibited the GGF2-
dependents increase in [ 3H]thymidine incorporation into
NRVM by GGF2 could be inhibited. Similarly, an antibody
directed against the C-terminus of ErbB4 also blocked about
15 50% of the increase in [ 3H]thymidine incorporation induced
by GGF2. A combination of these two antibodies had the
same effect as either the anti-ErbB2 or anti-ErbB4 antibodies
alone. In contrast, an antibody to ErbB3 had no effect on
GGF2-induced DNA synthesis. To verify that the effects seen
20 with the ErbB2 and ErbB4 antibodies were specific for GGF,
sister NRVM primary cultures were treated with 20 ng/ml
rhFGF2 (recombinant human bFGF). Neither antibody had
any effect on the approximately 2-fold increase in [3H]thy-
midine incorporation with rhFGF2. These results suggest that
25 
at least two of the known neuregulin receptor tyrosine kinases
were present and coupled to downstream signalling cascades
in the neonatal ventricular myocyte.
GGF2 Promotes Cardiac Myocyte Survival In Vitro
30 During development, the net increase in the number of
functional embryonic myocytes is dependent on both myo-
cyte proliferative capacity and survival. Therefore, it was of
interest to determine whether GGF2 could promote survival
of cardiac myocytes in addition to proliferation. Primary cul-
35 tures of NRVM maintained in serum-free medium, with or
without 10 µM of cytosine arabinoside (AraQ, were treated
with the indicated concentrations of GGF2 for 4 days, and the
relative numbers of metabolically active cells were deter-
40 
mined by a MTT cell respiration assay (see Methods). Data
are expressed as a percentage of the mean MTT activity of
myocytes in triplicate culture dishes on day 0 at the time of the
addition of GGF2. Data are shown as mean±SD (n=3 experi-
ments; *, p<0.05 vs control). We observed that approximately
45 25% of cells die by day 4. In contrast, addition of GGF2
resulted in a 30% increase in MTT activity compared to
controls. The effect was concentration-dependent with an
EC50 of 0.2 ng/ml (FIG. 5). This survival effect was observed
in NRVM primary cultures for up to 7 days; it was also
50 observed in the presence of cytosine arabinoside (AraQ, an
antiproliferative agent. As shown in FIG. 5, the survival effect
of GGF2 was observed at 4 days in the continuous presence of
cytosine arabinoside, with about 90% myocyte viability in the
presence of 50 ng/ml rhGGF2 compared to approximately
55 70% viability in control cultures. In contrast, GGF2 had no
significant effect on the survival of myocyte-depleted, "non-
myocyte"-enriched primary isolates at 4 days.
We examined next whether the survival effect of GGF2 was
60 mediated by inhibition of programmed cell death (apoptosis).
Primary cultures of NRVM 2 days in serum-free medium
were maintained in either the absence of rhGGF2 (FIG.
6A-6C) or in the presence of 20 ng/ml of rhGGF2 (FIG.
6E-6G) for 4 days. Cells were then fixed and stained with
65 anti-MHC antibody and a TRITC-conjugated secondary anti-
body to visualize myocytes (FIGS. 6A and 6E) or with fluo-
rescein-conjugated dUTP (i.e., TUNEL) to reveal apoptotic
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cells (FIGS. 6B and 6F). The TUNEL-positive myocytes
displayed cell shrinkage and chromatin condensation, which
were also identified by Hoescht 33258-staining (FIGS. 6C
and 6G). Apoptosis was quantified either by counting the
number of TUNEL-positive myocytes (FIG. 6D) or by flow
cytometry analysis of the sub-GI fraction following pro-
pidium iodine-staining of primary NRVM cultures that had
been treated for 4 days with the indicated concentrations of
rhGGF2 (H). The data shown for FIG. 6D and FIG. 6H are
given as mean±S.D for three independent experiments. The
scale bar in FIGS. 6A-6C and 6E-6G represents 10 µM.
After 6 days in serum-free medium, about 17% of NRVM
maintained under control conditions at low density (i.e., sub-
confluent) exhibited evidence of apoptosis as detected by
TUNEL staining, with small condensed nuclei and cell
shrinkage consistent with apoptotic cell death (FIGS. 6A-6C
and 6E-6G). In the presence of 20 ng/ml rhGGF2, the number
of TUNEL positive myocytes declined to about 8% (FIG.
6D). The effect of GGF2 on inhibiting apoptosis was also
quantified using flow cytometric analysis of propidium
iodide-labelled NRVM primary cultures. After 4 days in
serum- and insulin-free medium, 22% of NRVM were hypo-
diploid, consistent with initiation of programmed cell death.
In the presence of rhGGF2 at concentrations above 10 ng/ml,
less than 10% of NRVM exhibited evidence of apoptosis
(FIG. 6H).
The survival and antiapoptotic effects of GGF2 on the adult
rat ventricular myocyte (ARVM) were also examined by
MTT cell respiration assay and TUNEL staining. In the
experiment shown in FIG. 7A, primary cultures of ARVM
were maintained in either a serum- and insulin-free medium
(i.e., ACCTT", see Methods), or ACCTT medium plus
GGF2 for 6 days. The number of metabolically active cells
was determined by the MTT cell respiration assay, and the
data are expressed as the relative absorbance normalized to
the mean absorbance of untreated, control cells. Each bar
represents the mean±S.D (n=3 experiments; *, p<0.05 vs
control). In the experiment shown in FIG. 713, primary cul-
tures of ARVM were maintained inACCTT medium (control)
orACCTT medium plus rhGGF2 (25 ng/ml) for 3 days. After
fixation with 4% paraformaldehyde, myocytes were visual-
ized with an anti-MHC antibody and a TRITC-conjugated
secondary antibody, and apoptotic cells were identified by
TUNEL staining. About 500 myocytes were counted on each
coverslip (data are mean±S.D of three independent experi-
ments; *, p<0.05 versus control). When compared to
untreated ARVM primary cultures, in which more than 10%
of cells were positive for TUNEL labelling, rhGGF2 (20
ng/ml)-treated adult myocyte cultures exhibited only about
3% TUNEL-positive staining (FIG. 713). These results indi-
cate neuregulins act as survival factors at least in part by
preventing programmed cell death in both neonatal and adult
ventricular myocytes.
GGF2 Induces Hypertrophic Growth of Cardiac Myocytes
In order to investigate whether neuregulin signalling can
induce a hypertrophic (growth) response in cardiac myocytes,
we examined the effects of GGF2 on induction of myocyte
hypertrophy in both neonatal and adult rat ventricular myo-
cyte primary cultures. FIGS. 8A and 8B show photomicro-
graphs of subconfluent NRVM primary isolates incubated
either without (FIG. 8A) or with (FIG. 813) rhGGF2 (20
ng/ml) for 72 h in serum-free medium, after which cells were
fixed and stained with an antibody to cardiac MHC (red,
TRITC) and examined using indirect immunofluorescence
microscopy. The scale bar shown in the figure represents
10 µM. After a 72-hr incubation in serum-free medium with
20
20 ng/ml (i.e., 0.36 nM) of rhGGF2, neonatal cardiac myo-
cytes (NRVM) exhibited a significant increase in cell size and
in myofibrillar development.
A hypertrophic response in cardiac myocytes is character-
s ized by a number of phenotypic changes in addition to an
increase in cell size, such as an increase in contractile protein
content without cellular proliferation and the re-activation of
an "embryonic" gene program. Therefore, we examined the
to effects of neuregulin on levels of prepro-ANF and skeletal
a-actin mRNA (transcripts normally found in relatively low
abundance in neonatal and adult ventricular myocytes), and
on [3 H]leucine incorporation as an index of protein synthesis
in NRVM primary cultures. FIG. 8C shows a Northern blot
15 analysis for prepro-ANF and skeletal a-actin mRNA from
total RNA (20 µg/lane) from NRVM incubated either with or
without rhGGF2 (20 ng/ml) for the times indicated. Equal
loading and transfer of RNA were confirmed by GAPDH
hybridization. RhGGF2 (20 ng/ml) increased mRNA levels
20 for prepro-ANF and skeletal-actin within 60 min, approxi-
mately doubling by 16 h.
To test the effect of GGF2 on protein synthesis, NVRM
were cultured in serum-free medium for 24h, after which they
were treated with the indicated concentrations of rhGGF2 for
25 40 h, and pulsed with [ 3H]leucine for 8 h before termination
of GGF2 stimulation. The incorporation of [3 H]leucine at
each concentration of GGF2 was normalized to the protein
content of each dish, and data are expressed as relative cpm/
30 dish normalized to the mean cpm of untreated control cells in
each experiment (mean±S.D.; n=3 experiments; *, p<0.01 vs
control). FIG. 8D shows that GGF2 also stimulated [3H]
leucine incorporation, with about a 120% increase at 48 h, at
a concentration of 5 ng/ml. To minimize possible confound-
35 ing effects of GGF2 on the rate of [ 3H]leucine uptake into
non-myocyte contaminant cells, these experiments were
repeated in the continuous presence of cytosine arabinoside
with similar results.
GGF2 also caused hypertrophic responses in cultured adult
4o 
rat ventricular myocytes (ARVM). Primary cultures of
ARVM were plated on coverslips in 24-well dishes and main-
tained for 5 days in ACCITT medium either without (FIG.
9A) or with rhGGF2 (20 ng/ml) (FIGS. 9B and 9C). Cells
45 were fixed in 4% paraformaldehyde, stained with an antibody
to myosin heavy chain (green, FITC), and examined by con-
focal microscopy. The scale bars represent 10 µM. By 72 h in
the continuous presence of 20 ng/ml of rhGGF2, some adult
myocytes had begun to develop "pseudopod"-like extensions,
50 primarily from the region of the intercalated discs, and by 5
days, more than 60% of the GGF-treated adult cardiomyo-
cytes displayed phenotypic changes consistent with those
illustrated in FIGS. 9B and 9C, whereas more than 80% of
untreated ARVM maintained the phenotype exhibited in FIG.
55 9A.
GGF2 also enhanced expression of prepro-ANF and skel-
etal a-actin in ARVM. Primary isolates of ARVM were
stimulated either with or without 20 ng/ml rhGGF2 for the
times indicated. Total RNA was isolated and analyzed by
6o Northern blot (25 µg/lane) using prepro-ANF and skeletal
(a-actin cDNA probes. Equal loading and transfer conditions
were confirmed by GAPDH hybridization. Phenylephrine
(PE, 10 µM) was used as a positive control for hypertrophic
growth. As shown in FIG. 9D, rhGGF2 (20 ng/ml) doubled
65 prepro-ANF mRNA abundance in ARVM primary cultures
after 8 h, and this had increased 3- to 4-fold within 20 h. An
increase in skeletal (a-actin mRNA abundance was also
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observed that was greater than that seen with phenylephrine EXAMPLE III
(10 ltM), an a-adrenergic agonist known to induce hyper-
trophic growth and reexpression of a number of fetal genes in ErbB2 and ErbB4 Expression Levels Decrease in
adult rat ventricular myocytes. Within 7 h, skeletal a-actin Aortic Stenosis Rats in Transition from Chronic
mRNA levels were easily detectable, and increased by an 5 Hypertrophy to Early Heart Failure
additional 250%by 30 h treatment with GGF2. Neither GGF2
nor phenylephrine had any effect on GAPDH mRNA abun- LV Hypertrophy and Hemodynamics
dance under the conditions employed here. As shown in Table 1, left ventricular (LV) weight and the
To test the effect of GGF2 on protein synthesis, ARVM (2 to LV/body weight ratio were significantly (p<0.05) increased
days in ACCITT medium) were stimulated with increasing in the 6-week and 22-week aortic stenosis animals compared
concentrations of rhGGF2 for 40 h and [ H]leucine was
added during the last 14 h. [ H]Leucine uptake in GGF2- with age-matched controls. The in vivo LV systolic pressure
treated cultures was normalized to the mean of [3H]leucine was significantly increased in both 6-week and 22- week
15
uptake in non-stimulated control myocytes. Data were also aortic stenosis animals compared with age-matched controls. 
normalized to protein content of each dish to adjust for any In vivo LV end-diastolic pressure was also higher in aortic
variability in cell number among dishes (mean±S.D; n=4; *, stenosis animals compared to age-matched controls. Consis-
p<0.01 vs control). As illustrated in FIG. 9E, GGF2 induced tent with prior studies in this model, LV systolic developed
a dose-dependent increase in [3 H]leucine incorporation, with 20 pressure per gram was significantly higher in 6-week aortic
a 70% increase at a concentration of 5 ng/ml. Thus, this stenosis animals in comparison with age-matched controls,
neuregulin induces phenotypic changes consistent with but depressed in 22-week aortic stenosis animals. At 22-week
hypertrophic adaptation in both neonatal and adult rat ven- post banding, the aortic stenosis animals also showed clinical
tricular myocyte phenotypes at subnanomolar concentra- markers of failure including tachypnea, small pleural and
tions. pericardial effusions.
TABLE 1
Left Ventricular Hypertrophy and Hemodynamics
C (6 wks)	 LVH (6 wks) C (22-wks) LVH (22 wks)
BW (g)	 397 ± 10	 378 ± 15	 590 ± 10	 564 ± 19
LV Wt (g)	 1.25 ± 0.05	 1.58 ± 0.06* 1.64 ± 0.07 	 2.46 ± 0.10*
LV Wt/BW (g/kg)	 3.18±0.13	 4.40±0.21* 2.84±0.14	 4.41±0.20*
LVEDP (mmHg)	 4.8 ± 0.3	 12.4 ± 0.7*	 6.5 ± 0.8	 15.7 ± 1.0*
LVSP(mmHg)	 104±3	 181±7*	 129±5	 182±9*
LVdevP/g (mmHg/g)	 84.2 ± 5.2	 108.1 ± 6.8*	 82.4 ± 7.8	 68.1 ± 4.2*
Table 1 Legend:
LVH, hearts with left ventricular hypertrophy, 6 and 22 weeks after aortic stenosis;
C, age-matched controls;
BW, body weight;
LV Wt, left ventricular weight;
LVEDP, LV end-diastolic pressure;
LVSP, LV systolic pressure;
LV devP, LV developed pressure per gram. Values are mean ± SEM;
*p <0.05 vs. age-matched controls;
_p < 0.05 vs. 6-weeks LVH. n = 14-20 per group.
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Expression of LV ErbB2, ErbB4 and Neuregulin in Aortic
Stenosis
Using RT-PCR, we were able to detect ErbB2, ErbB4 and
neuregulin mRNA, but not ErbB3 mRNA, in LV tissue
derived from hearts of adult male rats with and without left
ventricular hypertrophy, as well as in normal and hypertro-
phied myocytes. FIG. 10A shows a ribonuclease protection
assay demonstrating LV ErbB2 and R -actin mRNA expres-
sion in 6-week aortic stenosis hearts and controls, and in
22-week aortic stenosis hearts and controls. FIG. 10B shows
a ribonuclease protection assay demonstrating LV ErbB4 and
R -actin mRNA expression in 6-week aortic stenosis hearts
and controls, and 22-week aortic stenosis hearts and controls.
Steady state levels of ErbB2, ErbB4 and neuregulin mRNA
levels in LV tissue from aortic stenosis rats and controls (n=5
hearts per group) were then measured by ribonuclease pro-
tection assay (RPA) and normalized to (3-actin. The LV neu-
regulin mRNA levels were not significantly different in tissue
from 6-week aortic stenosis rats compared to age-matched
controls (0.68±0.12 vs. 0.45±0.12 units, NS) or 22-week
aortic stenosis rats compared to age-matched controls
(0.78±0.21 vs. 0.51±0.21 units, NS). Moreover, the LV
ErbB2 and ErbB4 mRNA levels, which were normalized to
levels of (3-actin, were preserved in 6-week aortic stenosis rats
with compensatory hypertrophy relative to controls. In con-
trast LV ErbB2 (p<0.05) and ErbB4 (p<0.01) message levels
were significantly depressed in 22-week aortic stenosis rats at
the stage of early failure (FIG. 10 and Table 2).
TABLE 2
LV mRNA and Protein Levels of ErbB Receptors
24
group). Neuregulin was not detectable by RPA in RNA
derived from myocytes in any group.
ErbB2 (n=5 per group) and ErbB4 (n=34 per group) mes-
sage levels were also measured in myocyte RNA from both
5 aortic stenosis groups (FIG. 12 and Table 2). FIG. 12A shows
a ribonuclease protection assay demonstrating LV myocyte
ErbB2 and R -actin mRNA expression in 6-weeks aortic
stenosis hearts and controls, and 22-weeks aortic stenosis
hearts and controls. FIG. 12B shows a ribonuclease protec-
10 tion assay demonstrating LV myocyte ErbB4 and R -actin
mRNA expression in 6-week aortic stenosis hearts and con-
trols, and 22-week aortic stenosis hearts and controls. Con-
sistent with the measurements in LV tissues samples, cardi-
omyocyte ErbB2 and ErbB4 mRNA levels, normalized to
15 R -actin levels, are preserved relative to controls in 6-week
aortic stenosis animals at the stage of compensatory hyper-
trophy (NS). However, both ErbB2 and ErbB4 expression are
significantly downregulated in 22-week aortic stenosis ani-
mals at the transition to failure (p<0.01).
20
LV ErbB2 and ErbB4 Protein Levels
Western blotting using polyclonal antibodies for ErbB2
and ErbB4 was performed using protein samples derived
from LV tissue of 6-week and 22-week aortic stenosis rats in
25 comparison with age-matched controls (n=5 per group).
FIGS. 13A and 13B show Western blots showing LV ErbB2
and R -actin protein levels in 6-week (FIG. 13A) aortic steno-
sis hearts and controls, and 22-week (FIG. 1313) aortic steno-
C (6 wks)	 LVH (6 wks)	 C (22-wks)	 LVH (22 wks)
mRNA (LV)
ErbB2	 0.354 ± 0.016	 0.326 ± 0.028	 0.528 ± 0.072	 0.301 ± 0.027*
ErbB4	 1.158 ± 0.036	 1.088 ± 0.062	 1.236 ± 0.050	 0.777 ± 0.082**
mRNA (myocyte)
ErbB2 0.755 ± 0.066 0.683 ± 0.027 1.609 ± 0.089 0.493 ± 0.035**
ErbB4 0.291 ± 0.024 0.266 ± 0.012 0.346 ± 0.023 0.182 ± 0.014**
protein (LV)
ErbB2 1.228 ± 0.107 1.073 ± 0.092 1.218 ± 0.198 0.638 ± 0.065*
ErbB4 2.148 ± 0.180 1.968 ± 0.150 1.446 ± 0.119 0.828 ± 0.068**
Table 2 Legend:
LVH, hearts with left ventricular hypertrophy, 6 and 22 weeks after aortic stenosis;
C, age-matched controls;
left ventricular (LV) mRNA levels were measured by ribonuclease protection assay and nor-
malized to P-actin;
mRNA levels were measured in RNA from both LV tissue (mRNA, LV,
n = 5 hearts per group) and from LV myocytes (mRNA, myocyte; ErbB2 n = 5 hearts per
group; ErbB4 n = 3-4 hearts per group).
LV protein levels were measured in LV tissue (n = 5 per group) by Western blotting and
normalized to P- actin.
Values are mean ± SEM;
*p < 0.05 vs. age-matched controls;
**p <0.01 vs. age-matched controls.
We next examined gene expression in RNA from LV myo-
cytes of 6-week and 22-week aortic stenosis animals and
controls. The specificity of expression in myocytes was deter-
mined by examining message levels of atrial natriuretic pep-
tide (ANP), a positive molecular marker of pressure overload
hypertrophy, using myocyte RNA and normalization to levels
of GAPDH. As shown in FIG. 11, ANP was upregulated in
myocytes from both 6-week (710±16 vs. 230±40 units,
p<0.05) and 22-weeks aortic stenosis animals (898±52 vs.
339±13 units, p<0.05) in comparison with controls (n=5 per
sis hearts and controls. FIGS. 13C and 13D show Western
blots showing LV ErbB4 and P-actinprotein levels in 6-week
60 (FIG. 13C) aortic stenosis hearts and controls, and 22-week(FIG. 13D) aortic stenosis hearts and controls. Densitometric
signals of each receptor were normalized to signals of (3-actin.
As shown in FIGS. 13A-13D and Table 2, ErbB2 and ErbB4
mRNA expression is preserved relative to controls in 6-weeks
65 aortic stenosis animals at the stage of compensatory hyper-
trophy (NS) but ErbB2 (p<0.05) and ErbB4 (p<0.01) are
downregulated in 22-week aortic stenosis animals during
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early failure. Thus, a decrease inboth LV message andprotein	 One of skill in the art will fully comprehend and know how
levels of ErbB2 and ErbB4 is present at the stage of early 	 to perform the experiments needed to determine the optimal
failure in this model of pressure overload. 	 neuregulin dosage regimen (e.g., amount of dose, frequency
Antisense digoxigenin-labeled mRNA of neuregulin gen-
erated reproducible hybridization signals on LV cryosections,
whereas the corresponding sense transcript generated no sig-
nal above background. Neuregulin signals in adult heart cryo-
sections were observed in the endothelial cells of the cardiac
microvasculature with minimal or no signal in other cell
compartments. There was no difference between control and
aortic stenosis animals.
In Situ Hybridization for Neuregulin 	 of administration o timal time durin the disease course toF	 g5 initiate neuregulin treatment) for minimizing, preventing, or
even reversing congestive heart disease.
EXAMPLE IV	 15
Inhibition of Heart Failure in Aortic Stenosis Mice
by Polypeptides that Contain a Neuregulin-1
EGF-like Domain
The Examples above describe data showing that rhGGF2 20
suppresses apoptosis and stimulates cardiomyocyte hypertro-
phy in an ErbB2- and ErbB4-dependent fashion. Moreover,
ErbB2 and ErbB4 receptors are down-regulated in the left
ventricles of rats with pressure overload-induced heart fail- 25
ure. Cardiomyocyte apoptosis is extremely rare during the
early compensatory hypertrophic stage in aortic stenosis mice
(i.e., 4 weeks after aortic banding), but consistently appears
during the transition to early heart failure (i.e., 7 weeks after
aortic banding).	 30
These above observations indicate that administration of
polypeptides that have an EGF-like domain encoded by a
neuregulin gene will be useful in inhibiting the progression of
and/or protecting against congestive heart failure. While not
wishing to be bound by theory, it is likely that neuregulin 35
treatment will strengthen the pumping ability of the heart by
stimulating cardiomyocyte hypertrophy, and partially or
completely prevent further deterioration of the heart by sup-
pressing cardiomyocyte apoptosis.
One of ordinary skill in the art can readily determine the 40
optimal dosage regimen required for providing prophylaxis
against congestive heart disease or for slowing or halting
progression of already-existent heart disease, using one of the
many animals models for congestive heart failure that are
known in the art. For example, as a starting point, the relative 45
efficacy of a 0.3 mg/kg dose of GGF2 administered at early
stages and late stages of cardiac disease in the aortic stenosis
mouse model may be assessed as follows.
Group 1 (n=6); treated: injections of rhGGF2 (0.3 mg/kg
given on alternate days), initiated 48 hours after aortic band- 50
ing and continued through week 7.
Group 2 (n=6); treated: injections of rhGGF2 (0.3 mg/kg
given on alternate days), initiated at the beginning of week 4
after aortic banding and continued through week 7.
Group 3 (n=6); control: sham injections, initiated 48 hours 55
after aortic banding and continued through week 7.
Group 4 (n=6); control: sham injections, initiated at the
beginning of week 4 after aortic banding and continued
through week 7.
Animals are sacrificed at the end of week 7. Prior to sacri- 60
fice, left ventricular hemodynamics are measured as
described in Example I above, or using any standard protocol.
Confocal microscopy may be used to quantitate myocyte
growth (hypertrophy) and myocyte apoptosis by in situ nick-
end labeling (TUNEL) or similar techniques for measuring 65
cell death, using standard protocols or as described in
Example I.
EXAMPLE V
The anthracycline antibiotics (e.g., daunorubicin, and
doxorubicin) have been a mainstay of cancer chemotherapy
for more than 20 years. However, the short- and long-term
cardiotoxicity of these drugs limits both the individual dose
and the cumulative dose that can be delivered to a patient.
There are two clinical types of anthracycline-induced car-
diotoxicity. The acute type, which can occur after a single
dose of anthracycline, is characterized by electrocardio-
graphic changes, arrhythmias, and a reversible decrease in
ventricular contractile function. The chronic, delayed type is
characterized by a largely irreversible decrease in ventricular
contractile function which progresses to dilated cardiomy-
opathy and congestive heart failure. The incidence of this
chronic cardiotoxicity is in direct proportion to the cumula-
tive anthracycline dose.
We have found that GGF2 (NRG-1) inhibits anthracycline-
induced apoptosis in rat cardiac myocytes. FIG. 14 shows that
rat cardiomyocyte cultures pre-treated with IGF-1 or NRG-1
are less susceptible to apoptosis (indicated by TUNEL stain-
ing) induced by 1 µM daunorubicin. For IGF-1 this protective
effect is rapid, and can be achieved within 30 minutes of
pre-incubation, similar to what was reported for fetal cardiac
myocytes. In contrast, this effect takes 24 hours of pre-incu-
bation with NRG-1.
FIG. 15A shows that both IGF-1 and NRG-1 cause rapid
phosphorylation of Akt (FIG. 15A), and that this is inhibited
by the PI-3 kinase inhibitor wortmannin. Akt has been impli-
cated in mediating survival signals in some systems through
phosphorylation and inactivation of the pro-apoptotic protein
caspase 3. Either thirty minutes of pre-incubation with IGF-1
or 24 hours of pre-incubation with NRG-1 prevent anthracy-
cline-induced activation of caspase 3. This effect, as well as
the survival effect of IGF-1, is completely prevented by wort-
mannin (FIG. 1513). Thus, activation of PI-3 kinase is neces-
sary for the cytoprotective effect of IGF on myocytes. How-
ever, the lack of cytoprotection by NRG-1 over the same time
course indicates that activation of PI-3 kinase and Akt is not
sufficient for cytoprotection. The relatively long NRG-1
exposure period needed for cytoprotection suggests that
NRG-1-dependent protection of cardiomyocytes against apo-
ptosis requires de novo protein synthesis. Consistent with this
observation, treatment of the cells with cyclohexamide inhib-
its the anti-apoptotic effect of NRG-1 on cardiomyocytes.
The results described above show that NRG-1 effectively
inhibits anthracycline-induced apoptosis. Therefore, NRG-1
could be used to limit or prevent cardiotoxicity in patients
undergoing anthracycline chemotherapy and to treat patients
that have congestive heart failure caused by cardiotoxicity
induced by anthracyclines or other cardiotoxic agents.
Existing in the art are various well known animal models of
anthracycline-induced cardiotoxicity. Mouse, rat, rabbit,
hamster, dog, swine, and monkey models for assessing the
relative efficacy of therapeutic compounds for ameliorating
anthracycline-induced cardiotoxicity are described in `Ame-
lioration of Chemotherapy Induced Cardiotoxicity" Semin.
10	 NRG-1 Inhibits Anthracycline-induced Apoptosis in
Rat Cardiac Myocytes
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Oncol. 25(4)Suppl. 10, August 1998 (see, e.g., Myers, Semin.
Oncol. 25:10-14, 1998; Herman and Ferrans, Semin. Oncol.
25:15-21, 1998; and Imondi, Semin. Oncol. 25:22-30, 1998).
These models may be used to determine the optimal neuregu-
lin or neuregulin-like polypeptide treatment regimen (e.g.,
amount and frequency of dosage, and timing relative to
anthracycline administration), for minimizing, preventing, or
reversing anthracycline-induced cardiotoxicity.
EXAMPLE VI
Neuregulin-dependent Inhibition of Cardiac Failure
Induced by Anthracycline/Anti-ErbB2 (Anti-HER2)
Combination Therapy
Various types of cancer cells display increased expression
or increased biological activity of ErbB receptors. These
transmembrane receptor tyrosine kinases bind growth factors
belonging to the neuregulin (also known as heregulin) family.
Expression of the ErbB2 receptor (also known as HEP2 and
neu) in cancer cells has been correlated with increases in
proliferation of carcinoma cells derived from various tissues,
including, but not limited to, breast, ovary, prostate, colon,
pancreas, and salivary gland.
Recently, it has been shown that HERCEPTIN® (Trastu-
zumab; Genentech, Inc., South San Francisco, Calif.), a
humanized monoclonal antibody that specifically binds the
extracellular domain of the human ErbB2 (HER2) receptor,
inhibits the growth of breast carcinoma cells in vitro and in
vivo by down-regulating ErbB2 activity. A Phase III clinical
trial evaluating the safety and efficacy of combining HER-
CEPTIN® therapy with traditional anthracycline (doxorubi-
cin) chemotherapy in breast cancer patients showed that
patients receiving the combination therapy displayed greater
tumor shrinkage and inhibition of cancer progression than
patients receiving either therapy alone. However, patients
receiving combination therapy also suffered increased car-
diotoxicity relative to patients receiving anthracycline
therapy alone, indicating that anti-ErbB2 (anti-HER2) anti-
bodies such as HERCEPTIN® increase anthracycline-in-
28
duced cardiotoxicity. In addition, patients that had previously
been treated with doxorubicin and later received HERCEP-
TIN® also showed an increased incidence of cardiotoxicity,
relative to patients treated with doxorubicin alone.
5 Given the recently-shown success of HERCEPTIN®/an-
thracycline combination therapy in ameliorating ErbB2-over-
expressing breast tumors, it is likely that similar combination
therapies will soon be used to treat other ErbB2-overexpress-
ing tumors. However, the benefit/risk ratio of anti-ErbB2
10 antibody/anthracycline combination therapy would be
greatly improved if its associated cardiotoxicity could be
decreased or prevented.
Animal models of anthracycline-induced cardiotoxicity
(see, e.g., Herman and Ferrans, Semin. Oncol. 25:15-21,1998
15 and Herman et al. Cancer Res. 58:195-197, 1998) are well-
known in the art. Moreover, antibodies that block neuregulin
binding to ErbB2 receptors, such as those described above,
are well-known. By inducing anthracycline/anti-ErbB2 anti-
body-dependent heart failure in known animal models for
20 anthracycline toxicity, one of skill in the art will readily be
able to determine the neuregulin dosage regimen required to
minimize or prevent such heart failure.
OTHER EMBODIMENTS
25
All publications and patent applications mentioned in this
specification are herein incorporated by reference to the same
extent as if each independent publication or patent applica-
tion was specifically and individually indicated to be incor-
30 porated by reference.
While the invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications and this application is
intended to cover any variations, uses, or adaptations of the
35 invention following, in general, the principles of the invention
and including such departures from the present disclosure
come within known or customary practice within the art to
which the invention pertains and may be applied to the essen-
tial features hereinbefore set forth, and follows in the scope of
the appended claims.
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 14
<210> SEQ ID NO 1
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 1
tgtgctagtc aagagtccca accac 	 25
<210> SEQ ID NO 2
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 2
ccttctctcg gtactaagta ttcag 	 25
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-continued
<210> SEQ ID NO 3
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 3
gcttaaagtg cttggctcgg gtgtc	 25
<210> SEQ ID NO 4
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 4
tcctacacac tgacactttc tctt 	 24
<210> SEQ ID NO 5
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 5
aattcaccca tcagagtgac gtttgg	 26
<210> SEQ ID NO 6
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 6
tcctgcaggt agtctgggtg ctg	 23
<210> SEQ ID NO 7
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 7
gctggctccg atgtatttga tggt	 24
<210> SEQ ID NO 8
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 8
gttctctgcc gtaggtgtcc cttt	 24
<210> SEQ ID NO 9
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
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-continued
<400> SEQUENCE: 9
gcatcactgg ctgattctgg ag	 22
<210> SEQ ID NO 10
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide
<400> SEQUENCE: 10
cacatgccgg ttatggtcag ca	 22
<210> SEQ ID NO 11
<211> LENGTH: 754
<212> TYPE: PRT
<213> ORGANISM: Rattus norvegicus
<400> SEQUENCE: 11
Met Arg Arg Asp Pro Ala Pro Gly Phe Ser Met Leu Leu Phe Gly Val
1	 5	 10	 15
Ser Leu Ala Cys Tyr Ser Pro Ser Leu Lys Ser Val Gin Asp Gin Ala
20	 25	 30
Tyr Lys Ala Pro Val Val Val Glu Gly Lys Val Gin Gly Leu Ala Pro
35	 40	 45
Ala Gly Gly Ser Ser Ser Asn Ser Thr Arg Glu Pro Pro Ala Ser Gly
50	 55	 60
Arg Val Ala Leu Val Lys Val Leu Asp Lys Trp Pro Leu Arg Ser Gly
65	 70	 75	 80
Gly Leu Gin Arg Glu Gin Val Ile Ser Val Gly Ser Cys Ala Pro Leu
85	 90	 95
Glu Arg Asn Gin Arg Tyr Ile Phe Phe Leu Glu Pro Thr Glu Gin Pro
100	 105	 110
Leu Val Phe Lys Thr Ala Phe Ala Pro Val Asp Pro Asn Gly Lys Asn
115	 120	 125
Ile Lys Lys Glu Val Gly Lys Ile Leu Cys Thr Asp Cys Ala Thr Arg
130	 135	 140
Pro Lys Leu Lys Lys Met Lys Ser Gin Thr Gly Glu Val Gly Glu Lys
145	 150	 155	 160
Gin Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gin Pro Ser Tyr
165	 170	 175
Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg
180	 185	 190
Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser Arg Leu Gin Phe Asn Lys
195	 200	 205
Val Lys Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile
210	 215	 220
Leu Gly Lys Asp Thr Val Arg Gly Arg Leu His Val Asn Ser Val Ser
225	 230	 235	 240
Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr
245	 250	 255
Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly
260	 265	 270
Ile Asn Gin Leu Ser Cys Lys Cys Pro Val Gly Tyr Thr Gly Asp Arg
275	 280	 285
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34
-continued
Cys Gln Gln Phe Ala Met Val Asn Phe Ser Lys His Leu Gly Phe Glu
290	 295	 300
Leu Lys Glu Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr
305	 310	 315	 320
Gly Ile Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val Val Ala
325	 330	 335
Tyr Cys Lys Thr Lys Lys Gln Arg Arg Gln Met His His His Leu Arg
340	 345	 350
Gln Asn Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn Gly Pro
355	 360	 365
Ser His Pro Arg Leu Asp Pro Glu Glu Ile Gln Met Ala Asp Tyr Ile
370	 375	 380
Ser Lys Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu Ala Glu
385	 390	 395	 400
Thr Thr Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His Cys Ser
405	 410	 415
Thr Ala Thr Pro Thr Ser Ser His Arg His Glu Ser His Thr Trp Ser
420	 425	 430
Leu Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly Ile Met
435	 440	 445
Leu Ser Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys Val Glu
450	 455	 460
Ala Arg Ala Arg Arg Ala Ala Ala Tyr Ser Gln Glu Glu Arg Arg Arg
465	 470	 475	 480
Ala Ala Met Pro Pro Tyr His Asp Ser Ile Asp Ser Leu Arg Asp Ser
485	 490	 495
Pro His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg Leu
500	 505	 510
Ser Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro Thr Phe
515	 520	 525
Glu Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro Pro Ala
530	 535	 540
Ala Pro Ile Ser Tyr Arg Leu Ala Glu Gln Gln Pro Leu Leu Gly His
545	 550	 555	 560
Pro Ala Pro Pro Gly Pro Gly Pro Gly Pro Gly Ala Asp Met Gln Arg
565	 570	 575
Ser Tyr Asp Ser Tyr Tyr Tyr Pro Ala Ala Gly Pro Gly Pro Arg Arg
580	 585	 590
Gly Ala Cys Ala Leu Gly Gly Ser Leu Gly Ser Leu Pro Ala Ser Pro
595	 600	 605
Phe His Ile Pro Glu Asp Asp Glu Tyr Glu Thr Thr Gln Glu Cys Ala
610	 615	 620
Pro Pro Pro Pro Pro Arg Pro Arg Thr Arg Gly Ala Ser Arg Arg Thr
625	 630	 635	 640
Ser Ala Gly Pro Arg Arg Trp Arg Arg Ser Arg Leu Asn Gly Leu Ala
645	 650	 655
Ala Gln Arg Ala Arg Ala Ala Arg Asp Ser Leu Ser Leu Ser Ser Gly
660	 665	 670
Ser Gly Cys Gly Ser Ala Ser Ala Ser Asp Asp Asp Ala Asp Asp Ala
675	 680	 685
Asp Gly Ala Leu Ala Ala Glu Ser Thr Pro Phe Leu Gly Leu Arg Ala
690	 695	 700
Ala His Asp Ala Leu Arg Ser Asp Ser Pro Pro Leu Cys Pro Ala Ala
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705	 710	 715	 720
Asp Ser Arg Thr Tyr Tyr Ser Leu Asp Ser His Ser Thr Arg Ala Ser
725	 730	 735
Ser Arg His Ser Arg Gly Pro Pro Thr Arg Ala Lys Gin Asp Ser Gly
740	 745	 750
Pro Leu
<210> SEQ ID NO 12
<211> LENGTH: 330
<212> TYPE: PRT
<213> ORGANISM: Rattus norvegicus
<400> SEQUENCE: 12
Met Arg Arg Asp Pro Ala Pro Gly Phe Ser Met Leu Leu Phe Gly Val
1	 5	 10	 15
Ser Leu Ala Cys Tyr Ser Pro Ser Leu Lys Ser Val Gin Asp Gin Ala
20	 25	 30
Tyr Lys Ala Pro Val Val Val Glu Gly Lys Val Gin Gly Leu Ala Pro
35	 40	 45
Ala Gly Gly Ser Ser Ser Asn Ser Thr Arg Glu Pro Pro Ala Ser Gly
50	 55	 60
Arg Val Ala Leu Val Lys Val Leu Asp Lys Trp Pro Leu Arg Ser Gly
65	 70	 75	 80
Gly Leu Gin Arg Glu Gin Val Ile Ser Val Gly Ser Cys Ala Pro Leu
85	 90	 95
Glu Arg Asn Gin Arg Tyr Ile Phe Phe Leu Glu Pro Thr Glu Gin Pro
100	 105	 110
Leu Val Phe Lys Thr Ala Phe Ala Pro Val Asp Pro Asn Gly Lys Asn
115	 120	 125
Ile Lys Lys Glu Val Gly Lys Ile Leu Cys Thr Asp Cys Ala Thr Arg
130	 135	 140
Pro Lys Leu Lys Lys Met Lys Ser Gin Thr Gly Glu Val Gly Glu Lys
145	 150	 155	 160
Gin Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gin Pro Ser Tyr
165	 170	 175
Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg
180	 185	 190
Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser Arg Leu Gin Phe Asn Lys
195	 200	 205
Val Lys Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile
210	 215	 220
Leu Gly Lys Asp Thr Val Arg Gly Arg Leu His Val Asn Ser Val Ser
225	 230	 235	 240
Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr
245	 250	 255
Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly
260	 265	 270
Ile Asn Gin Leu Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gin Arg
275	 280	 285
Cys Leu Glu Lys Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gin
290	 295	 300
Ser Val Leu Trp Asp Thr Pro Gly Thr Gly Val Ser Ser Ser Gin Trp
305	 310	 315	 320
Ser Thr Ser Pro Ser Thr Leu Asp Leu Asn
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325	 330
<210> SEQ ID NO 13
<211> LENGTH: 182
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 13
Arg Gly Glu Gly Ile Ser Phe Pro Ser Lys Leu Gin Gly His Cys Gly
1	 5	 10	 15
Ser Val Glu Arg Gly Asn Arg Trp Val Thr Ala Gly Glu Pro Gin Pro
20	 25	 30
Ala Leu Ala His Ala Ser Pro Pro Phe Ile Pro Ser Leu Thr Arg Lys
35	 40	 45
Asn Ser Arg Leu Gin Phe Asn Lys Val Lys Val Glu Asp Ala Gly Glu
50	 55	 60
Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr Val Arg Gly
65	 70	 75	 80
Arg Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser Ser Trp Ser Gly
85	 90	 95
His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys Val Asn Gly
100	 105	 110
Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gin Leu Ser Cys Lys Cys
115	 120	 125
Pro Asn Gly Phe Phe Gly Gin Arg Cys Leu Glu Lys Leu Pro Leu Arg
130	 135	 140
Leu Tyr Met Pro Asp Pro Lys Gin Ser Val Leu Trp Asp Thr Pro Gly
145	 150	 155	 160
Thr Gly Val Ser Ser Ser Gin Trp Ser Thr Ser Pro Lys Pro Arg Ser
165	 170	 175
Cys Thr Arg Arg Gly Ser
180
<210> SEQ ID NO 14
<211> LENGTH:	 3020
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE:	 14
cctccaggtc ctggcgcaca gggtgggagc gctgcgctgc gccgcgctgc gcatcgcggc 60
ccgcttgccg cctgccccct gccctagctg ggccacctcc ccgggctgcc ggtggagggc 120
taagaggcgc taacgttacg ctgtttccgg ttttccagcg ggctctgttt cccctcccaa 180
ggcggcggcg gctgagcggc ggagcccccc aaatggcctg gccagatgcg gcaggtttgc 240
tgctcagcgc tgccgccgcc gccactggag aagggtcggt gcagcagcta cagcgacagc 300
agcagcagca gcagcgagag gagcagcagc agcagcagca gcagcagcga gagcggcagc 360
agcagcagga gcagcagcaa caacagcagc atctctcgtc ccgctgcgcc cccagagccg 420
cggccgcagc aacagccgca gccccgcagc cccgcagccc ggagagccgc cgcccgttcg 480
cgagccgcag ccgccggcgg catgaggcgc gacccggccc ccggcttctc catgctgctc 540
ttcggtgtgt cgctcgcctg ctactcgccc agcctcaagt cagtgcagga ccaggcgtac 600
aaggcacccg tggtggtgga gggcaaggta caggggctgg tcccagccgg cggctccagc 660
tccaacagca cccgagagcc gcccgcctcg ggtcgggtgg cgttggtaaa ggtgctggac 720
aagtggccgc tccggagcgg ggggctgcag cgcgagcagg tgatcagcgt gggctcctgt 780
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gtgccgctcg aaaggaacca gcgctacatc tttttcctgg agcccacgga acagccctta 	 840
gtctttaaga cggcctttgc ccccctcgat accaacggca aaaatctcaa gaaagaggtg 	 900
ggcaagatcc tgtgcactga ctgcgccacc cggcccaagt tgaagaagat gaagagccag 	 960
acgggacagg tgggtgagaa gcaatcgctg aagtgtgagg cagcagccgg taatccccag 	 1020
ccttcctacc gttggttcaa ggatggcaag gagctcaacc gcagccgaga cattcgcatc 	 1080
aaatatggca acggcagaaa gaactcacga ctacagttca acaaggtgaa ggtggaggac 	 1140
gctggggagt atgtctgcga ggccgagaac atcctgggga aggacaccgt ccggggccgg 	 1200
ctttacgtca acagcgtgag caccaccctg tcatcctggt cggggcacgc ccggaagtgc 	 1260
aacgagacag ccaagtccta ttgcgtcaat ggaggcgtct gctactacat cgagggcatc 	 1320
aaccagctct cctgcaaatg tccaaatgga ttcttcggac agagatgttt ggagaaactg 	 1380
cctttgcgat tgtacatgcc agatcctaag caaaaagccg aggagctgta ccagaagagg 	 1440
gtcctgacca tcacgggcat ctgcgtggct ctgctggtcg tgggcatcgt ctgtgtggtg 	 1500
gcctactgca agaccaaaaa acagcggaag cagatgcaca accacctccg gcagaacatg 	 1560
tgcccggccc atcagaaccg gagcttggcc aatgggccca gccacccccg gctggaccca 	 1620
gaggagatcc agatggcaga ttatatttcc aagaacgtgc cagccacaga ccatgtcatc 	 1680
aggagagaaa ctgagaccac cttctctggg agccactcct gttctccttc tcaccactgc 	 1740
tccacagcca cacccacctc cagccacaga cacgagagcc acacgtggag cctggaacgt 	 1800
tctgagagcc tgacttctga ctcccagtcg gggatcatgc tatcatcagt gggtaccagc 	 1860
aaatgcaaca gcccagcatg tgtggaggcc cgggcaaggc gggcagcagc ctacaacctg 	 1920
gaggagcggc gcagggccac cgcgccaccc tatcacgatt ccgtggactc ccttcgcgac 	 1980
tccccacaca gcgagaggta cgtgtcggcc ctgaccacgc ccgcgcgcct ctcgcccgtg 	 2040
gacttccact actcgctggc cacgcaggtg ccaactttcg agatcacgtc ccccaactcg 	 2100
gcgcacgccg tgtcgctgcc gccggcggcg cccatcagtt accgcctggc cgagcagcag 	 2160
ccgttactgc ggcacccggc gccccccggc ccgggacccg gacccgggcc cgggcccggg 	 2220
cccggcgcag acatgcagcg cagctatgac agctactatt accccgcggc ggggcccgga 	 2280
ccgcggcgcg ggacctgcgc gctcggcggc agcctgggca gcctgcctgc cagccccttc 	 2340
cgcatccccg aggacgacga gtacgagacc acgcaggagt gcgcgccccc gccgccgccg 	 2400
cggccgcgcg cgcgcggtgc gtcccgcagg acgtcggcgg ggccccggcg ctggcgccgc 	 2460
tcgcgcctca acgggctggc ggcgcagcgc gcacgggcgg cgagggactc gctgtcgctg 2520
agcagcggct cgggcggcgg ctcagcctcg gcgtcggacg acgacgcgga cgacgcggac 	 2580
ggggcgctgg cggccgagag cacacctttc ctgggcctgc gtggggcgca cgacgcgctg 2640
cgctcggact cgccgccact gtgcccggcg gccgacagca ggacttacta ctcactggac 	 2700
agccacagca cgcgggccag cagcagacac agccgcgggc cgcccccgcg ggccaagcag 2760
gactcggcgc cactctaggg ccccgccgcg cgcccctccg ccccgcccgc cccactatct 	 2820
ttaaggagac cagagaccgc ctactggaga gaaaggagga aaaaagaaat aaaaatattt 	 2880
ttattttcta taaaaggaaa aaagtataac aaaatgtttt attttcattt tagcaaaaat 	 2940
tgtcttataa tactagctaa cggcaaaggc gtttttatag ggaaactatt tatatgtaac 	 3000
atcctgattt acagcttcgg 	 3020
What is claimed is:
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1.A method for treating congestive heart failure in a mam-
mal, said method comprising administering a polypeptide
comprising an epidermal growth factor-like (EGF-like)
domain to said mammal, wherein said EGF-like domain is
encoded by a neuregulinNRG-2 gene, wherein said polypep-
tide comprises the amino acid sequence of SEQ ID NO: 11
and said administering is in an amount effective to treat con-
gestive heart failure in said mammal.
2. The method of claim 1, wherein said mammal is a
human.
3. The method of claim 1, wherein said congestive heart
failure results from hypertension; ischemic heart disease;
exposure to a cardiotoxic compound; myocarditis; thyroid
disease; viral infection; gingivitis; drug abuse; alcohol abuse;
periocarditis; atherosclerosis; vascular disease; hypertrophic
cardiomyopathy; acute myocardial infarction; left ventricular
systolic dysfunction; coronary bypass surgery; starvation; an
eating disorder; or a genetic defect.
4. The method of claim 3, wherein said mammal has under-
gone a myocardial infarction.
5. The method of claim 3, wherein said cardiotoxic com-
pound is an anthracycline, alcohol, or cocaine.
6. The method of claim 5, wherein said anthracyline is
doxorubicin, or daunomycin.
7. The method of claim 3, wherein said cardiotoxic com-
pound is an anti-ErbB2 or anti-HER2 antibody.
8. The method of claim 3, wherein said polypeptide is
administered prior to, during, or after exposure to said car-
diotoxic compound.
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9. The method of claim 1, wherein said polypeptide is
administered after the diagnosis of congestive heart failure in
said mammal.
10. The method of claim 1, wherein said polypeptide is
5 administered to a mammal that has undergone compensatory
cardiac hypertrophy.
11. The method of claim 1, wherein administration of said
polypeptide maintains left ventricular hypertrophy.
12. The method of claim 1, wherein said method decreases
io progression of myocardial thinning.
13. The method of claim 1, wherein administration of said
polypeptide inhibits cardiomyocyte apoptosis.
14. A method for treating congestive heart failure in a
mammal, said method comprising:
15 administering a polypeptide comprising an epidermal
growth factor-like (EGF-like) domain to said mammal,
wherein said epidermal growth factor-like (EGF-like)
domain consists essentially of the amino acid sequence
of SEQ ID NO: 11 and said administering is in an
20	 amount effective to treat heart failure in said mammal.
15. A method for treating congestive heart failure in a
mammal, said method comprising:
administering a polypeptide comprising an epidermal
growth factor-like (EGF-like) domain to said mammal,
25 wherein said epidermal growth factor-like (EGF-like)
domain comprises the EGF-like domain of SEQ ID NO:
11 and said administering is in an amount effective to
treat congestive heart failure in said mammal.
